oxybutynin has been researched along with Urinary Incontinence in 244 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Urinary Incontinence: Involuntary loss of URINE, such as leaking of urine. It is a symptom of various underlying pathological processes. Major types of incontinence include URINARY URGE INCONTINENCE and URINARY STRESS INCONTINENCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of oxybutynin transdermal gel 3% (OTG3%), with propylene glycol for enhanced skin permeation, in patients with urinary incontinence (UI)." | 9.20 | Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. ( Goldfischer, ER; Peters-Gee, J; Sand, PK; Thomas, H, 2015) |
| "Cizolirtine citrate is a promising agent in the treatment of OAB with urinary incontinence." | 9.14 | Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. ( Abadías, M; Brod'ák, M; Pavlík, I; Schraml, P; Sust, M; Villoria, J; Vsetica, J; Zát'ura, F, 2010) |
| "The aim of this study was to evaluate the efficacy and safety of a new PO controlled-release (CR) QD oxybutynin tablet relative to PO immediate-release (IR) TID oxybutynin in patients with urge urinary incontinence (UI)." | 9.11 | A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. ( Barkin, J; Corcos, J; Darke, AC; Harsanyi, Z; Jammal, MP; Miceli, PC; Radomski, S; Reiz, JL, 2004) |
| "We compare the tolerability and efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with nonneurogenic diurnal urinary incontinence and symptoms of overactive bladder." | 9.10 | Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. ( Crocker, J; Reinberg, Y; Vandersteen, D; Wolpert, J, 2003) |
| "We evaluated the efficacy and safety of an oxybutynin transdermal delivery system (TDS) in a general population of patients with overactive bladder and urge or mixed urinary incontinence." | 9.10 | Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. ( Davila, GW; Dmochowski, RR; Gittelman, MC; Lyttle, S; Saltzstein, DR; Sanders, SW; Zinner, NR, 2002) |
| "To determine if oxybutynin, a bladder relaxant medication, adds to the effectiveness of prompted voiding (PV) in the management of urinary incontinence among nursing home residents." | 9.08 | Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. ( Fingold, S; Jensen, BB; Nigam, JG; Ouslander, JG; Schnelle, JF; Tuico, E; Uman, G, 1995) |
| "To examine the response to conversion from regular oxybutynin (Ditropan) to an extended-release form (Ditropan XL) in children with persistent daytime urinary incontinence." | 7.73 | Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin. ( Austin, JC; Cooper, CS; Knudson, MJ; Van Arendonk, KJ, 2006) |
| "To assess the clinical efficacy of tolterodine prescribed to children with non-neurogenic daytime urinary incontinence secondary to overactive bladder who had previously failed to improve with oral oxybutynin treatment and its relation to the side-effect profile and compliance status." | 7.73 | Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? ( Akkaya, E; Akman, S; Baykara, M; Danisman, A; Guntekin, E; Kukul, E; Yucel, S, 2005) |
| " The cardiac electrophysiological effects of S-oxybutynin, a single-enantiomer drug under evaluation for the management of urinary incontinence, have been investigated and compared with those of terodiline, an incontinence agent withdrawn following reports of QT lengthening and ventricular tachyarrhythmia." | 7.70 | Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials. ( Jones, SE; McCullough, JR; McDonald, TF; Shuba, LM; Zhabyeyev, P, 2000) |
| "The effects and the safety of oxybutynin hydrochloride were investigated in 52 patients, 17 male and 35 female, with the chief complaints of pollakisuria, urgency and urinary incontinence." | 7.68 | [Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence]. ( Hashimoto, H; Inagaki, N; Ohashi, K; Osanai, H; Yachiku, S; Yamaguchi, S; Yamauchi, K, 1990) |
| " The incidence of adverse events (AEs) was similar in the three treatment groups (extended-release oxybutynin, 70%; extended-release tolterodine, 64%; and immediate-release tolterodine, 79%)." | 6.73 | Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. ( Armstrong, RB; Dmochowski, RR; Macdiarmid, S; Sand, PK, 2007) |
| " After an initial placebo run-in period, dosing in each began at 5 mg per day and increased weekly by 5 mg per day to a maximum of 20 mg per day or when a balance between improvement of incontinence symptoms and tolerability of side effects was achieved." | 6.69 | Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. ( Appell, R; Mobley, D; Patton, W; Saltzstein, D; Versi, E, 2000) |
| "Oxybutynin was marginally superior to tolterodine in decreasing the number of incontinent episodes in a 24-hour period (weighted mean difference, 0." | 6.41 | Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. ( Baker, K; Harvey, MA; Wells, GA, 2001) |
| "To compare the results of the standard urotherapy alone and associated with pelvic floor muscle training alone, and in combination with oxybutynin in treatment of nonmonosymptomatic nocturnal enuresis." | 5.30 | Pelvic floor muscle training alone or in combination with oxybutynin in treatment of nonmonosymptomatic enuresis. A randomized controlled trial with 2-year follow up. ( Campos, RM; D'Ancona, CAL; Glazer, HI; Hacad, CR; Lopes, MHBM; Lúcio, AC; Perissinotto, MCR, 2019) |
| "Cizolirtine citrate is a promising agent in the treatment of OAB with urinary incontinence." | 5.14 | Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. ( Abadías, M; Brod'ák, M; Pavlík, I; Schraml, P; Sust, M; Villoria, J; Vsetica, J; Zát'ura, F, 2010) |
| "To assess the efficacy, incidence of dry mouth and overall satisfaction with initial doses of 5, 10 and 15 mg of a new, once-daily, controlled-release (CR) form of oxybutynin for treating urge urinary incontinence (UUI)." | 5.12 | A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. ( Andreou, C; Casey, R; Corcos, J; Darke, AC; Harsanyi, Z; Miceli, PC; Patrick, A; Reiz, JL, 2006) |
| "Reductions in urge urinary incontinence episodes were similar with tolterodine and oxybutynin in children with DI." | 5.12 | Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. ( Akgoz, S; Balkan, E; Dogruyol, H; Kilic, N; Sen, N, 2006) |
| "To evaluate the effects of tolterodine and oxybutynin on visual accommodation, pupillary diameter, intraocular pressure and tear secretion in women with overactive bladder." | 5.11 | Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. ( Altan-Yaycioglu, R; Aydin Akova, Y; Guvel, S; Ozkardes, H; Yaycioglu, O, 2005) |
| "The safety and efficacy of oxybutynin transdermal delivery system (oxybutynin-TDS) versus placebo in adults with urge and mixed urinary incontinence was investigated using combined results from double-blind stages of 2 phase 3 clinical trials." | 5.11 | Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. ( Appell, R; Davila, GW; Dmochowski, RR; Luber, K; Nitti, V; Staskin, D, 2005) |
| "We evaluated the efficacy and safety of an oxybutynin transdermal delivery system (TDS) in a general population of patients with overactive bladder and urge or mixed urinary incontinence." | 5.10 | Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. ( Davila, GW; Dmochowski, RR; Gittelman, MC; Lyttle, S; Saltzstein, DR; Sanders, SW; Zinner, NR, 2002) |
| "We compare the tolerability and efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with nonneurogenic diurnal urinary incontinence and symptoms of overactive bladder." | 5.10 | Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. ( Crocker, J; Reinberg, Y; Vandersteen, D; Wolpert, J, 2003) |
| " Extended-release formulations of oxybutynin at 10 mg/d or tolterodine at 4 mg/d were given for 12 weeks to women with 21 to 60 urge urinary incontinence (UUI) episodes per week and an average of 10 or more voids per 24 hours." | 5.10 | Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. ( Appell, RA; Diokno, AC; Dmochowski, RR; Gburek, BM; Kell, SH; Klimberg, IW; Sand, PK, 2003) |
| "Oxybutynin is used for the treatment of urge urinary incontinence." | 5.09 | Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. ( Gupta, SK; Sathyan, G, 1999) |
| "Nine patients with persistent urinary incontinence due to neurogenic bladder and intolerable systemic side effects on oral anticholinergic agents were treated with intravesical instillation of oxybutynin hydrochloride." | 5.08 | [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization]. ( Ishiura, Y; Nakamura, Y; Ohkawa, M; Yokoyama, O, 1995) |
| "Oxybutynin hydrochloride (Pollakisu tablets) was administered at a daily dose of 6 or 9 mg to 75 elderly patients with urinary tract disorders, including neurogenic bladder and unstable bladder, with chief complaints of pollakisuria, urgency on urination and urinary incontinence." | 5.07 | [Assessment of the use of oxybutynin hydrochloride (Pollakisu tablets) in the elderly]. ( Hisazumi, H; Nakajima, K; Nihino, A; Uchibayashi, T, 1991) |
| " The search terms were overactive bladder, urinary incontinence, trospium, randomized controlled clinical trial, oxybutynin, tolterodine, scopolamine, imipramine, desipramine, and propantheline." | 4.82 | Trospium chloride for the treatment of overactive bladder with urge incontinence. ( Machado, C; Singh-Franco, D; Tuteja, S; Zapantis, A, 2005) |
| "To determine whether there is greater risk of initiation of oxybutynin to treat urinary incontinence (UI) after initiation of medicines reported to be associated with UI." | 3.80 | Risk of medication-associated initiation of oxybutynin in elderly men and women. ( Barratt, JD; Kalisch Ellett, LM; Pratt, NL; Roughead, EE; Rowett, D, 2014) |
| "Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence." | 3.74 | The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. ( Gupta, SK; Huang, Y; Parker, MH; Reitz, AB; Ryan, RR, 2007) |
| "To examine the variables relative to the response of oxybutynin treatment in children with daytime urinary incontinence." | 3.73 | Frequency of wetting is predictive of response to anticholinergic treatment in children with overactive bladder. ( Austin, JC; Boyt, MA; Cooper, CS; Van Arendonk, KJ, 2006) |
| "To assess the clinical efficacy of tolterodine prescribed to children with non-neurogenic daytime urinary incontinence secondary to overactive bladder who had previously failed to improve with oral oxybutynin treatment and its relation to the side-effect profile and compliance status." | 3.73 | Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? ( Akkaya, E; Akman, S; Baykara, M; Danisman, A; Guntekin, E; Kukul, E; Yucel, S, 2005) |
| "Oxybutynin and tolterodine are two drugs widely used for the management of overactive bladder and urge urinary incontinence." | 3.72 | Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. ( Dubois, D; Hughes, DA, 2004) |
| " Furthermore, NS-21 increased the bladder capacity without suppressing micturition pressure, suggesting that NS-21 may be a more effective therapeutic drug than propiverine, oxybutynin or flavoxate for the treatment of urinary frequency and urinary incontinence." | 3.69 | Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency. ( Hamada, K; Kimura, K; Kimura, Y; Sasaki, Y; Seto, T; Ukai, Y; Yamazaki, C; Yoshikuni, Y, 1997) |
| "Intravesical oxybutynin hydrochloride was administered to 17 patients with a neuropathic bladder (myelomeningocele in 15 and spinal cord tumour in two) and urinary incontinence refractory to intermittent catheterisation." | 3.69 | Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder. ( Chiba, K; Kaneko, S; Miyata, M; Mizunaga, M; Yachiku, S, 1994) |
| "The effect of intravesical oxybutynin hydrochloride on detrusor behaviour was studied in 15 patients with urinary incontinence due to detrusor hyper-reflexia by ambulatory bladder monitoring." | 3.68 | Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia. ( O'Flynn, KJ; Thomas, DG, 1993) |
| "Intravesical oxybutynin chloride was administered to 10 children with neurogenic bladder (myelomeningocele in 9 and imperforate anus in 1) and urinary incontinence refractory to regimens of intermittent catheterization and oral anticholinergic medication." | 3.68 | The use of intravesical oxybutynin chloride in children with neurogenic bladder. ( Fera, M; Greenfield, SP, 1991) |
| "The effects and the safety of oxybutynin hydrochloride were investigated in 52 patients, 17 male and 35 female, with the chief complaints of pollakisuria, urgency and urinary incontinence." | 3.68 | [Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence]. ( Hashimoto, H; Inagaki, N; Ohashi, K; Osanai, H; Yachiku, S; Yamaguchi, S; Yamauchi, K, 1990) |
| "Fesoterodine has a favorable benefit-risk profile in 6‒<18-year-old patients with NDO and may represent an additional option for pediatric NDO treatment." | 3.30 | Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study. ( Crook, TJ; Darekar, A; Jones, P; Kitta, T; Lindsay, M; Malhotra, B; Mallen, S; Nieto, A; Shahin, MH, 2023) |
| "Postmenopausal women with an overactive bladder were recruited from the general gynecology clinic." | 2.76 | Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. ( Felix, JC; Leegant, AR; Mishell, DR; Nelken, RS; Ozel, BZ, 2011) |
| " The incidence of adverse events (AEs) was similar in the three treatment groups (extended-release oxybutynin, 70%; extended-release tolterodine, 64%; and immediate-release tolterodine, 79%)." | 2.73 | Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. ( Armstrong, RB; Dmochowski, RR; Macdiarmid, S; Sand, PK, 2007) |
| "Oxybutynin 15 mg was more effective than propiverine 20 mg in reducing symptomatic and asymptomatic IDCs in ambulatory patients." | 2.72 | Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. ( Abrams, P; Cardozo, L; Chapple, C; Hargreaves, K; Khullar, V; Serdarevic, D, 2006) |
| "Oxybutynin was more effective than placebo." | 2.72 | Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. ( Chen, MC; Chih, SY; Wang, AC, 2006) |
| ", Mountain View, CA) at different dosages, compared with immediate-release oxybutynin (IR-O), and to determine the pharmacodynamic properties in the severity-dependent reduction of urge urinary incontinence (UUI)." | 2.71 | Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. ( Albrecht, D; Anderson, R; Hampel, C; O'Connell, M; Preik, M, 2004) |
| " Peak plasma concentrations of oxybutynin and the major active metabolite, N-desethyloxybutynin, are reached 24 - 48 hours after a single application and therapeutic concentrations are maintained throughout the dosage interval." | 2.71 | Transdermal oxybutynin: for overactive bladder. ( Bang, LM; Easthope, SE; Perry, CM, 2003) |
| "Modified intravesical oxybutynin is an effective and relatively safe option of therapy for overactive bladder patients." | 2.71 | Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. ( Miyagawa, I; Otsubo, K; Saito, M; Satoh, K; Tabuchi, F; Watanabe, T, 2004) |
| "The oxybutynin treated patients had a lower overall performance at baseline pretreatment testing." | 2.71 | The effect of oxybutynin treatment on cognition in children with diurnal incontinence. ( Askari, N; Kennedy, WA; Kraemer, HC; O'Hara, R; Sommer, BR, 2005) |
| "Darifenacin CR is an efficacious therapy for OAB with comparable effects on urodynamic parameters but producing significantly less dry mouth than oxybutynin." | 2.71 | Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. ( Abrams, P; Chapple, CR, 2005) |
| "Oxybutynin was randomly prescribed with a starting dose of either 2." | 2.71 | Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. ( Athanasiou, S; Cardozo, L; Kelleher, C; Khullar, V; Milani, R; Salvatore, S, 2005) |
| " The side effect profile (dry mouth) was comparable between tolterodine, 2 mg twice daily, and placebo, but differed significantly when comparing tolterodine SSD with oxybutynin SSD (P < 0." | 2.71 | Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. ( Bard, RJ; Casey, AR; Ethans, KD; Nance, PW; Schryvers, OI, 2004) |
| "Oxybutynin was absorbed from the bladder with a geometric mean Cmax of 9." | 2.70 | Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. ( Hakonen, T; Lehtoranta, K; Lukkari-Lax, E; Tainio, H; Tammela, TL, 2002) |
| "Urinary incontinence is a common condition caused by many factors with several treatment options." | 2.69 | Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. ( Burgio, KL; Candib, D; Dombrowski, M; Goode, PS; Hardin, JM; Locher, JL; McDowell, BJ, 1998) |
| "Propiverine is a safe and effective drug in the treatment of urgency and urge incontinence; it is as effective as oxybutynin, but the incidence of dry mouth and its severity is less with propiverine than with oxybutynin." | 2.69 | A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. ( Alloussi, S; Halaska, M; Höfner, K; Madersbacher, H; Voigt, R, 1999) |
| "Oxybutynin is an effective drug whose frequent adverse effects limit its clinical usefulness." | 2.69 | Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. ( Appell, RA; Drutz, HP; Gleason, D; Klimberg, I; Radomski, S, 1999) |
| " Four patients had stopped the medication and there was no difference in the distribution of maximum dosage achieved between the groups." | 2.69 | Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial. ( Adams, EJ; Richmond, DH; Sutherst, JR; Tincello, DG, 2000) |
| " After an initial placebo run-in period, dosing in each began at 5 mg per day and increased weekly by 5 mg per day to a maximum of 20 mg per day or when a balance between improvement of incontinence symptoms and tolerability of side effects was achieved." | 2.69 | Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. ( Appell, R; Mobley, D; Patton, W; Saltzstein, D; Versi, E, 2000) |
| " 21/32 patients became totally continent with the dosage (A)." | 2.69 | Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. ( Dörsam, J; Gerner, HJ; Haferkamp, A; Staehler, G, 2000) |
| "Describing a therapeutic index for a drug is important for evaluating safe and effective dosage regimens." | 2.69 | Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. ( Aarons, L; Gupta, SK; Ho, PL; Lindemulder, EA; Sathyan, G; Sheiner, LB, 1999) |
| "Oxybutynin is an efficacious pharmacotherapeutic agent for the treatment of urge incontinence." | 2.69 | Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. ( Bemelmans, BL; Debruyne, FM; Kiemeney, LA, 2000) |
| "Oxybutynin has long been used for the treatment of patients with detrusor overactivity and urinary urge incontinence." | 2.68 | Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. ( Haarala, M; Hakonen, T; Kiilholma, P; Kivelä, A; Lukkari, E; Nilsson, CG, 1997) |
| " Safety and tolerability were assessed from adverse events and laboratory measures." | 2.68 | Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. ( Appell, RA, 1997) |
| "Oxybutynin was superior to placebo in reducing daytime frequency [95% confidence interval (CI) of difference in change in frequencies totalled over 14 days was -27." | 2.68 | Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. ( Collas, DM; Ding, YY; Malone-Lee, JG; Szonyi, G, 1995) |
| " The AMs used to treat OAB differ in their pharmacological profiles, which may affect their potential for causing adverse effects (AEs)." | 2.48 | Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. ( Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL, 2012) |
| "Around 16% to 45% of adults have overactive bladder symptoms (urgency with frequency and/or urge incontinence - 'overactive bladder syndrome')." | 2.48 | Which anticholinergic drug for overactive bladder symptoms in adults. ( Cody, JD; Ellis, G; Hay-Smith, EJ; Herbison, GP; Madhuvrata, P, 2012) |
| "14]) but did not resolve urinary incontinence, with no significant dose-response association." | 2.44 | Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. ( Kane, RL; Shamliyan, TA; Wilt, TJ; Wyman, J, 2008) |
| " While trospium chloride dosage adjustments based on age or sex appear unwarranted, such adjustments may be needed in patients with severe renal impairment." | 2.42 | Trospium chloride in the management of overactive bladder. ( Rovner, ES, 2004) |
| " Similarly, the potential improvements in tolerability associated with different dosage formulations of oxybutynin, and the clinical utility of S-oxybutynin, are yet to be conclusively demonstrated." | 2.41 | Muscarinic receptor antagonists in the treatment of overactive bladder. ( Chapple, CR, 2000) |
| "Resiniferatoxin (RTX) is an ultrapotent capsaicin analog that has the significant advantage of being a nonirritant." | 2.41 | Intravesical treatment of overactive bladder. ( Fowler, CJ, 2000) |
| " Improvements in drug delivery systems have altered drug bioavailability and pharmacokinetics." | 2.41 | Advancements in pharmacologic management of the overactive bladder. ( Appell, RA; Dmochowski, RR, 2000) |
| "Oxybutynin was marginally superior to tolterodine in decreasing the number of incontinent episodes in a 24-hour period (weighted mean difference, 0." | 2.41 | Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. ( Baker, K; Harvey, MA; Wells, GA, 2001) |
| " A major limitation to long-term compliance with immediate-release oxybutynin remains the necessity for twice- or thrice-daily dosing regimens to provide sustained pharmacological efficacy." | 2.41 | Oxybutynin chloride: alterations in drug delivery and improved therapeutic index. ( Dmochowski, R; Kell, S; Staskin, D, 2002) |
| " The convenience of once-daily dosing of antimuscarinic agents would be expected to improve patient compliance and further relieve the symptoms of OAB." | 2.41 | Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. ( Rovner, ES; Wein, AJ, 2002) |
| " Despite short terminal disposition half-lives of 2-3 and 3-4 hours for tolterodine and its active 5-hydroxy metabolite, respectively, twice/day dosing is effective due to the drug's prolonged pharmacodynamic effects." | 2.40 | Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. ( Guay, DR, 1999) |
| " Pharmacokinetic studies have indicated a slow rise in mean plasma concentration of the isomer R-oxybutynin for 4 to 6 hours after a single dose of OROS oxybutynin, followed by maintenance of steady concentrations for up to 24 hours, minimizing the fluctuations between peak and trough associated with TID dosing of 5-mg immediate-release oxybutynin tablets." | 2.40 | An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. ( Goldenberg, MM, 1999) |
| "Terodiline is a new drug combining anticholinergic and calcium-blocking effects." | 2.38 | Functional daytime incontinence: pharmacological treatment. ( Chiozza, ML; Hjälmås, K; Passerini-Glazel, G, 1992) |
| " In 11 patients, oxybutynin could be stopped, and in 2 the dosage could be reduced to once daily." | 1.39 | Detrusorectomy reduces the need for augmentation and use of antimuscarinics in children with neuropathic bladders. ( Chrzan, R; de Jong, TP; Dik, P; Klijn, AJ; Kuijper, CF, 2013) |
| "Forty six patients with symptoms of overactive bladder, i." | 1.36 | In women with urinary incontinence how necessary is cystometry? ( Saleem, A, 2010) |
| "Oxybutynin-TDS was efficacious in spinal cord injury patients with neurogenic detrusor overactivity and was well tolerated at up to 3 times the standard dose." | 1.35 | Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. ( Foote, JE; Kennelly, MJ; Lemack, GE; Trop, CS, 2009) |
| "Oxybutynin has been used for treatment of urge urinary incontinence for more than 20 years." | 1.32 | Effectiveness of vaginally administered oxybutynin on rabbit bladder function. ( Borow, A; Burden, O; Leggett, RE; Levin, RM; Whitbeck, C, 2003) |
| "Treatment with oxybutynin decreased isovolumetric detrusor pressure in all 3 stop tests by up to 6 cm." | 1.32 | Which stop test is best? Measuring detrusor contractility in older females. ( Bergmann, MA; Griffiths, D; Resnick, NM; Tan, TL, 2003) |
| "Oxybutynin is a drug of choice in the treatment of the detrusor instability." | 1.31 | [Therapeutic effects of intrarectal administration of oxybutynin]. ( Borkowski, A; Radziszewski, P, 2002) |
| "Oxybutynin was discontinued significantly earlier (mean 45 days) than tolterodine (mean 59 days, p<0." | 1.31 | Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. ( Anderson, MJ; Benson, SR; Guay, DR; Lawrence, M, 2000) |
| " The majority of discontinuations were for adverse events; dry mouth was the most frequently cited event leading to discontinuation (8." | 1.31 | Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. ( Albrecht, D; Antoci, J; Atkinson, L; Diokno, A; Labasky, R; Leach, G; Sand, P; Sieber, P, 2002) |
| "Extended-release oxybutynin is safe and efficacious in children." | 1.31 | Preliminary study of the safety and efficacy of extended-release oxybutynin in children. ( Kogan, BA; Youdim, K, 2002) |
| "Urinary incontinence is a debilitating problem that requires careful evaluation." | 1.31 | The management of urinary incontinence in the exstrophy complex, posterior urethral valves, and infrasphincteric ureters. ( Wilcox, DT, 2002) |
| "Patients requiring CIC for neurogenic bladder but with incontinence that was unresponsive to standard oral therapy or that was associated with severe systemic side effects were studied over a 1-year period." | 1.30 | Intravesical therapy for the treatment of neurogenic bladder in children. ( Barker, AP; Chauvel, PJ; Holland, AJ; King, PA; McKnight, DL; O'Neill, MK, 1997) |
| "Oxybutynin is an effective drug to stop detrusor hyperactivity, but it has a high rate of anticholinergic adverse reactions." | 1.30 | [Management of hyposalivation caused by oxybutynin chloride in the treatment of the unstable bladder]. ( Arango Toro, O; Castro Santamaría, R; Cortadellas Angel, R; Gelabert Mas, A; Nohales Taurines, G, 1998) |
| "Whether incontinence after surgery for benign prostatic hypertrophy (BPH) requires simple workup and treatment or being a more complex condition and multifactorial in etiology requiring combined surgical techniques should be investigated in more detail." | 1.30 | Incontinence after surgery for benign prostatic hypertrophy: the case for complex approach and treatment. ( Floratos, D; Katsifotis, C; Mertziotis, N; Moutzouris, G; Plastiras, D; Theodorou, C, 1998) |
| " In all cases patients had been treated according to a normal dosage regimen." | 1.30 | [Neuropsychiatric adverse effects attributed to use of oxybutynin]. ( Kwee-Zuiderwijk, WJ; Stricker, BH; t'Veld, BA; van Puijenbroek, EP, 1998) |
| "The Williams syndrome is a relatively rare disease with characteristic facial appearance, mental retardation, growth deficiency, cardiovascular anomalies, hypercalcemia and multiple organic dysfunctions." | 1.30 | [Neuro-urological findings in Williams syndrome: report of a case]. ( Borrelli Júnior, M; Borrelli, M; Freire, Gde C; Marinelli, CM; Sakuramoto, PK; Spinola, RT; Tobias-Machado, M, 1998) |
| " The results of the study argue against the dosage regimen proposed before these adverse events were detected." | 1.29 | Plasma levels of oxybutynine chloride in children. ( Autret, E; Averous, M; Bertiere, MC; Couet, W; Dutertre, JP; Jonville, AP; Robert, M, 1994) |
| "Of 21 patients treated, 9 had neurogenic bladder and 10 had unstable bladder." | 1.28 | [Clinical effect of oxybutynin hydrochloride (1 mg/tablet)]. ( Fujino, A; Koshiba, K; Kubo, S; Mashimo, S; Yokoyama, E, 1990) |
| ") was not statistically different than the mean peak level reported after the same dosage in young healthy men (8." | 1.27 | Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. ( Blaustein, J; Connor, A; Orzeck, S; Ouslander, JG; Yong, CL, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (6.97) | 18.7374 |
| 1990's | 67 (27.46) | 18.2507 |
| 2000's | 137 (56.15) | 29.6817 |
| 2010's | 21 (8.61) | 24.3611 |
| 2020's | 2 (0.82) | 2.80 |
| Authors | Studies |
|---|---|
| Naito, R | 1 |
| Yonetoku, Y | 1 |
| Okamoto, Y | 1 |
| Toyoshima, A | 1 |
| Ikeda, K | 1 |
| Takeuchi, M | 1 |
| Moretti, E | 1 |
| Barbosa, L | 1 |
| da Silva, IB | 1 |
| de Lima, AMJ | 1 |
| Lemos, A | 1 |
| Kitta, T | 2 |
| Darekar, A | 2 |
| Malhotra, B | 2 |
| Shahin, MH | 2 |
| Jones, P | 2 |
| Lindsay, M | 2 |
| Mallen, S | 2 |
| Nieto, A | 2 |
| Crook, TJ | 2 |
| Brown, RS | 1 |
| Rhodes, BH | 1 |
| Siewe, MS | 1 |
| Matthews, TJ | 1 |
| Campos, RM | 1 |
| Lúcio, AC | 1 |
| Lopes, MHBM | 1 |
| Hacad, CR | 1 |
| Perissinotto, MCR | 1 |
| Glazer, HI | 1 |
| D'Ancona, CAL | 1 |
| Moga, DC | 1 |
| Carnahan, RM | 1 |
| Lund, BC | 1 |
| Pendergast, JF | 1 |
| Wallace, RB | 1 |
| Torner, JC | 1 |
| Li, Y | 1 |
| Chrischilles, EA | 1 |
| Hart, WM | 1 |
| Abrams, P | 3 |
| Munro, V | 1 |
| Retsa, P | 1 |
| Nazir, J | 1 |
| Goldfischer, ER | 1 |
| Sand, PK | 9 |
| Thomas, H | 1 |
| Peters-Gee, J | 1 |
| Rantell, A | 1 |
| Cardozo, L | 4 |
| Srikrishna, S | 1 |
| Snodgrass, W | 1 |
| Villaneuva, C | 1 |
| Jacobs, M | 1 |
| Gargollo, P | 1 |
| Kalisch Ellett, LM | 1 |
| Pratt, NL | 1 |
| Barratt, JD | 1 |
| Rowett, D | 1 |
| Roughead, EE | 1 |
| Trivedi, D | 1 |
| Yamaguchi, O | 1 |
| Uchida, E | 1 |
| Higo, N | 1 |
| Minami, H | 1 |
| Kobayashi, S | 1 |
| Sato, H | 1 |
| Harari, D | 2 |
| Igbedioh, C | 1 |
| Soljanik, I | 1 |
| Costantini, E | 1 |
| Lazzeri, M | 1 |
| Zát'ura, F | 1 |
| Vsetica, J | 1 |
| Abadías, M | 1 |
| Pavlík, I | 1 |
| Schraml, P | 1 |
| Brod'ák, M | 1 |
| Villoria, J | 1 |
| Sust, M | 1 |
| Chapple, CR | 3 |
| Kennelly, MJ | 1 |
| Lemack, GE | 2 |
| Foote, JE | 2 |
| Trop, CS | 1 |
| Saleem, A | 1 |
| Nelken, RS | 1 |
| Ozel, BZ | 1 |
| Leegant, AR | 1 |
| Felix, JC | 1 |
| Mishell, DR | 1 |
| Madhuvrata, P | 1 |
| Cody, JD | 1 |
| Ellis, G | 2 |
| Herbison, GP | 1 |
| Hay-Smith, EJ | 1 |
| Chrzan, R | 1 |
| Dik, P | 2 |
| Klijn, AJ | 2 |
| Kuijper, CF | 1 |
| de Jong, TP | 2 |
| Shamliyan, T | 1 |
| Wyman, JF | 1 |
| Ramakrishnan, R | 1 |
| Sainfort, F | 1 |
| Kane, RL | 2 |
| Leone Roberti Maggiore, U | 1 |
| Salvatore, S | 2 |
| Alessandri, F | 1 |
| Remorgida, V | 1 |
| Origoni, M | 1 |
| Candiani, M | 1 |
| Venturini, PL | 1 |
| Ferrero, S | 1 |
| Newman, DK | 1 |
| Dmochowski, RR | 10 |
| Davila, GW | 5 |
| Zinner, NR | 1 |
| Gittelman, MC | 1 |
| Saltzstein, DR | 1 |
| Lyttle, S | 1 |
| Sanders, SW | 2 |
| Leung, HY | 1 |
| Yip, SK | 1 |
| Cheon, C | 1 |
| Liu, YS | 1 |
| Lau, J | 1 |
| Wong, HK | 1 |
| Chung, KH | 1 |
| Appell, RA | 7 |
| Maloney, CM | 1 |
| Cafiero, M | 1 |
| Reinberg, Y | 1 |
| Crocker, J | 1 |
| Wolpert, J | 1 |
| Vandersteen, D | 1 |
| Staskin, DR | 2 |
| Diokno, A | 1 |
| Sand, P | 2 |
| Labasky, R | 1 |
| Sieber, P | 1 |
| Antoci, J | 1 |
| Leach, G | 1 |
| Atkinson, L | 1 |
| Albrecht, D | 2 |
| Tan, TL | 1 |
| Bergmann, MA | 1 |
| Griffiths, D | 2 |
| Resnick, NM | 2 |
| Bolduc, S | 1 |
| Upadhyay, J | 1 |
| Payton, J | 1 |
| Bägli, DJ | 1 |
| McLorie, GA | 1 |
| Khoury, AE | 1 |
| Farhat, W | 1 |
| Hader, C | 1 |
| Welz-Barth, A | 1 |
| Keller, T | 1 |
| Radziszewski, P | 1 |
| Borkowski, A | 1 |
| Levin, RM | 1 |
| Whitbeck, C | 1 |
| Borow, A | 1 |
| Burden, O | 1 |
| Leggett, RE | 1 |
| Halaska, M | 2 |
| Ralph, G | 1 |
| Wiedemann, A | 1 |
| Primus, G | 2 |
| Ballering-Brühl, B | 1 |
| Höfner, K | 2 |
| Jonas, U | 1 |
| de Kort, LM | 1 |
| Uiterwaal, CS | 1 |
| Ellsworth, P | 1 |
| Malone-Lee, J | 3 |
| Henshaw, DJ | 1 |
| Cummings, K | 1 |
| Richelson, E | 1 |
| Elliott, DS | 1 |
| Diokno, AC | 1 |
| Gburek, BM | 1 |
| Klimberg, IW | 1 |
| Kell, SH | 1 |
| Bang, LM | 1 |
| Easthope, SE | 1 |
| Perry, CM | 1 |
| Chancellor, M | 1 |
| Wagg, A | 2 |
| Homma, Y | 4 |
| Paick, JS | 1 |
| Lee, JG | 2 |
| Kawabe, K | 2 |
| Shultz, JM | 1 |
| Radomski, SB | 1 |
| Caley, B | 1 |
| Reiz, JL | 3 |
| Miceli, PC | 3 |
| Harsanyi, Z | 3 |
| Darke, AC | 3 |
| Goode, PS | 5 |
| Uemura, S | 1 |
| Saito, M | 1 |
| Watanabe, T | 1 |
| Tabuchi, F | 1 |
| Otsubo, K | 1 |
| Satoh, K | 1 |
| Miyagawa, I | 1 |
| Barkin, J | 1 |
| Corcos, J | 2 |
| Radomski, S | 2 |
| Jammal, MP | 1 |
| Preik, M | 1 |
| O'Connell, M | 1 |
| Hampel, C | 1 |
| Anderson, R | 1 |
| Ethans, KD | 1 |
| Nance, PW | 1 |
| Bard, RJ | 1 |
| Casey, AR | 1 |
| Schryvers, OI | 1 |
| Rovner, ES | 3 |
| Abramov, Y | 1 |
| Hughes, DA | 1 |
| Dubois, D | 1 |
| Giannitsas, K | 1 |
| Perimenis, P | 1 |
| Athanasopoulos, A | 1 |
| Gyftopoulos, K | 1 |
| Nikiforidis, G | 1 |
| Barbalias, G | 1 |
| Dull, P | 1 |
| Wagenlehner, FM | 1 |
| Yucel, S | 1 |
| Akkaya, E | 1 |
| Guntekin, E | 1 |
| Kukul, E | 1 |
| Danisman, A | 1 |
| Akman, S | 1 |
| Baykara, M | 1 |
| Rosenberg, MT | 1 |
| Khullar, V | 2 |
| Milani, R | 1 |
| Athanasiou, S | 1 |
| Kelleher, C | 2 |
| Altan-Yaycioglu, R | 1 |
| Yaycioglu, O | 1 |
| Aydin Akova, Y | 1 |
| Guvel, S | 1 |
| Ozkardes, H | 1 |
| Johnson, TM | 1 |
| Burgio, KL | 4 |
| Redden, DT | 1 |
| Wright, KC | 1 |
| Sommer, BR | 1 |
| O'Hara, R | 1 |
| Askari, N | 1 |
| Kraemer, HC | 1 |
| Kennedy, WA | 1 |
| Chu, FM | 1 |
| Lama, DJ | 1 |
| Anderson, RU | 2 |
| Singh-Franco, D | 1 |
| Machado, C | 1 |
| Tuteja, S | 1 |
| Zapantis, A | 1 |
| Gray, M | 1 |
| Hay-Smith, J | 1 |
| Herbison, P | 1 |
| Morris, A | 1 |
| Nuhoğlu, B | 1 |
| Fidan, V | 1 |
| Ayyildiz, A | 1 |
| Ersoy, E | 1 |
| Germiyanoğlu, C | 1 |
| Zinner, N | 2 |
| Tuttle, J | 1 |
| Marks, L | 1 |
| Karademir, K | 1 |
| Baykal, K | 1 |
| Sen, B | 1 |
| Senkul, T | 1 |
| Iseri, C | 1 |
| Erden, D | 1 |
| Armstrong, RB | 2 |
| Luber, KM | 1 |
| Peters, KM | 1 |
| Nitti, V | 1 |
| Staskin, D | 2 |
| Luber, K | 1 |
| Appell, R | 2 |
| Shaya, FT | 1 |
| Blume, S | 1 |
| Gu, A | 1 |
| Zyczynski, T | 1 |
| Jumadilova, Z | 4 |
| Nitz, NM | 1 |
| Darkow, T | 1 |
| Frytak, JR | 1 |
| Bavendam, T | 1 |
| Varadharajan, S | 1 |
| Girase, P | 1 |
| Ollendorf, DA | 1 |
| Perfetto, EM | 1 |
| Subedi, P | 1 |
| Angelico, P | 1 |
| Velasco, C | 1 |
| Guarneri, L | 1 |
| Sironi, G | 1 |
| Leonardi, A | 1 |
| Testa, R | 1 |
| Saltzstein, L | 1 |
| Nitti, VW | 1 |
| Getsios, D | 1 |
| El-Hadi, W | 1 |
| Caro, I | 1 |
| Caro, JJ | 1 |
| Evans, RJ | 1 |
| Leung, DY | 1 |
| Kwong, YY | 1 |
| Lam, DS | 1 |
| Taylor, PH | 1 |
| Sussman, DO | 1 |
| Agarwal, A | 1 |
| Dhiraaj, S | 1 |
| Singhal, V | 1 |
| Kapoor, R | 1 |
| Tandon, M | 1 |
| Kripke, C | 1 |
| Kim, Y | 1 |
| Yoshimura, N | 1 |
| Masuda, H | 1 |
| De Miguel, F | 1 |
| Chancellor, MB | 1 |
| Pannek, J | 1 |
| Grigoleit, U | 1 |
| Wormland, R | 1 |
| Goepel, M | 1 |
| Casey, R | 1 |
| Patrick, A | 1 |
| Andreou, C | 1 |
| MacDiarmid, SA | 1 |
| Guerrero, K | 1 |
| Emery, S | 1 |
| Owen, L | 1 |
| Rowlands, M | 1 |
| McCrery, RJ | 1 |
| Smith, PP | 1 |
| Schubert-Zsilavecz, M | 1 |
| Koyama, N | 1 |
| Sahai, A | 1 |
| Khan, MS | 1 |
| Arya, M | 1 |
| John, J | 1 |
| Singh, R | 1 |
| Patel, HR | 1 |
| Kilic, N | 1 |
| Balkan, E | 1 |
| Akgoz, S | 1 |
| Sen, N | 1 |
| Dogruyol, H | 1 |
| Van Arendonk, KJ | 2 |
| Austin, JC | 2 |
| Boyt, MA | 1 |
| Cooper, CS | 2 |
| Potter, DM | 1 |
| Griffiths, DJ | 2 |
| Grocela, JA | 1 |
| Kanji, A | 1 |
| Ternullo, J | 1 |
| Chapple, C | 1 |
| Serdarevic, D | 1 |
| Hargreaves, K | 1 |
| Tulikangas, PK | 1 |
| Ayers, A | 1 |
| O'Sullivan, DM | 1 |
| Haferkamp, A | 2 |
| Hohenfellner, M | 1 |
| Knudson, MJ | 1 |
| Wang, AC | 1 |
| Chih, SY | 1 |
| Chen, MC | 1 |
| Goldberg, RP | 1 |
| McIlwain, M | 1 |
| Dahl, NV | 2 |
| Cartwright, R | 1 |
| Newman, D | 1 |
| Lucente, V | 1 |
| Dmochowski, R | 2 |
| Macdiarmid, S | 1 |
| Takayanagi, R | 1 |
| Mizushima, H | 1 |
| Ozeki, T | 1 |
| Yokoyama, H | 1 |
| Iga, T | 1 |
| Yamada, Y | 1 |
| Almodhen, F | 1 |
| Capolicchio, JP | 1 |
| Jednak, R | 1 |
| El Sherbiny, M | 1 |
| Reitz, AB | 1 |
| Gupta, SK | 3 |
| Huang, Y | 1 |
| Parker, MH | 1 |
| Ryan, RR | 1 |
| Shamliyan, TA | 1 |
| Wyman, J | 1 |
| Wilt, TJ | 1 |
| Sink, KM | 1 |
| Thomas, J | 1 |
| Xu, H | 1 |
| Craig, B | 1 |
| Kritchevsky, S | 1 |
| Sands, LP | 1 |
| Riva, D | 1 |
| Casolati, E | 1 |
| Purcell, MH | 1 |
| Gregory, JG | 1 |
| Mundy, AR | 1 |
| Szonyi, G | 2 |
| Collas, DM | 1 |
| Ding, YY | 1 |
| Malone-Lee, JG | 2 |
| Enzelsberger, H | 2 |
| Kurz, C | 2 |
| Helmer, H | 2 |
| Mittermayer, F | 1 |
| Yarker, YE | 1 |
| Goa, KL | 1 |
| Fitton, A | 1 |
| Yokoyama, O | 1 |
| Ishiura, Y | 1 |
| Nakamura, Y | 1 |
| Ohkawa, M | 1 |
| Ouslander, JG | 3 |
| Schnelle, JF | 1 |
| Uman, G | 1 |
| Fingold, S | 1 |
| Nigam, JG | 1 |
| Tuico, E | 1 |
| Jensen, BB | 1 |
| Harrison, G | 1 |
| Moore, K | 1 |
| McCracken, P | 1 |
| Hernandez, RD | 1 |
| Hurwitz, RS | 1 |
| Zimmern, PE | 2 |
| Leach, GE | 2 |
| Autret, E | 1 |
| Jonville, AP | 1 |
| Dutertre, JP | 1 |
| Bertiere, MC | 1 |
| Robert, M | 1 |
| Averous, M | 1 |
| Couet, W | 1 |
| Mizunaga, M | 2 |
| Miyata, M | 2 |
| Kaneko, S | 2 |
| Yachiku, S | 3 |
| Chiba, K | 2 |
| Anderson, CL | 1 |
| Connor, JP | 1 |
| Betrus, G | 1 |
| Fleming, P | 1 |
| Perlmutter, AD | 1 |
| Reitelman, C | 1 |
| Sugiyama, T | 2 |
| Matsuda, H | 1 |
| Oonishi, N | 1 |
| Kiwamoto, H | 1 |
| Esa, A | 2 |
| Park, YC | 1 |
| Kurita, T | 2 |
| Uchida, A | 1 |
| Kunikata, S | 1 |
| López Pereira, P | 1 |
| Martínez, MJ | 1 |
| Muguerza, R | 1 |
| Jaureguizar, E | 1 |
| Weese, DL | 1 |
| Roskamp, DA | 1 |
| McCracken, PN | 1 |
| Harrison, GM | 1 |
| Moore, KN | 1 |
| Taniguchi, N | 1 |
| Osanai, H | 2 |
| Fujisawa, M | 1 |
| Hussain, RM | 1 |
| Hartigan-Go, K | 1 |
| Thomas, SH | 1 |
| Ford, GA | 1 |
| Shader, RI | 1 |
| Oesterheld, JR | 1 |
| Sasaki, Y | 1 |
| Hamada, K | 1 |
| Yamazaki, C | 1 |
| Seto, T | 1 |
| Kimura, Y | 1 |
| Ukai, Y | 1 |
| Yoshikuni, Y | 1 |
| Kimura, K | 1 |
| Hooper, P | 1 |
| Tincello, DG | 2 |
| Richmond, DH | 2 |
| Holland, AJ | 1 |
| King, PA | 1 |
| Chauvel, PJ | 1 |
| O'Neill, MK | 1 |
| McKnight, DL | 1 |
| Barker, AP | 1 |
| Schlozman, SC | 1 |
| Hennessey, JV | 1 |
| Nilsson, CG | 1 |
| Lukkari, E | 1 |
| Haarala, M | 1 |
| Kivelä, A | 1 |
| Hakonen, T | 2 |
| Kiilholma, P | 1 |
| Lurie, SN | 1 |
| Hosmer, C | 1 |
| Arango Toro, O | 1 |
| Nohales Taurines, G | 1 |
| Cortadellas Angel, R | 1 |
| Castro Santamaría, R | 1 |
| Gelabert Mas, A | 1 |
| Sung, VC | 1 |
| Corridan, PG | 1 |
| Arango, O | 1 |
| Theodorou, C | 1 |
| Moutzouris, G | 1 |
| Floratos, D | 1 |
| Plastiras, D | 1 |
| Katsifotis, C | 1 |
| Mertziotis, N | 1 |
| Hills, CJ | 1 |
| Winter, SA | 1 |
| Balfour, JA | 1 |
| t'Veld, BA | 1 |
| Kwee-Zuiderwijk, WJ | 1 |
| van Puijenbroek, EP | 1 |
| Stricker, BH | 1 |
| Vaidyananthan, S | 1 |
| Soni, BM | 1 |
| Brown, E | 1 |
| Sett, P | 1 |
| Krishnan, KR | 1 |
| Bingley, J | 1 |
| Markey, S | 1 |
| Amark, P | 2 |
| Bussman, G | 2 |
| Eksborg, S | 2 |
| Winkler, HA | 1 |
| Bayliss, M | 1 |
| Ingham, NJ | 1 |
| Arnold, K | 1 |
| Tobias-Machado, M | 1 |
| Marinelli, CM | 1 |
| Sakuramoto, PK | 1 |
| Spinola, RT | 1 |
| Borrelli Júnior, M | 1 |
| Freire, Gde C | 1 |
| Borrelli, M | 1 |
| Locher, JL | 3 |
| Hardin, JM | 1 |
| McDowell, BJ | 1 |
| Dombrowski, M | 1 |
| Candib, D | 1 |
| Juneskans, O | 1 |
| Palm, C | 1 |
| Khorsandi, M | 1 |
| Ginsberg, PC | 1 |
| Harkaway, RC | 1 |
| O'Flynn, KJ | 1 |
| Thomas, DG | 1 |
| Sathyan, G | 2 |
| Guay, DR | 2 |
| Mobley, D | 2 |
| Blank, B | 1 |
| Saltzstein, D | 2 |
| Susset, J | 2 |
| Brown, JS | 1 |
| Goldenberg, MM | 1 |
| Lindemulder, EA | 1 |
| Ho, PL | 1 |
| Sheiner, LB | 1 |
| Aarons, L | 1 |
| Hashimoto, K | 1 |
| Ohnishi, N | 1 |
| Park, Y | 1 |
| Gleason, DM | 1 |
| White, C | 1 |
| Munoz, DR | 1 |
| Madersbacher, H | 1 |
| Voigt, R | 1 |
| Alloussi, S | 1 |
| Drutz, HP | 1 |
| Gleason, D | 1 |
| Klimberg, I | 1 |
| Adams, EJ | 1 |
| Sutherst, JR | 1 |
| Fowler, CJ | 1 |
| Lawrence, M | 1 |
| Benson, SR | 1 |
| Anderson, MJ | 1 |
| Versi, E | 2 |
| Patton, W | 1 |
| Johansen, JK | 1 |
| Lose, G | 2 |
| Staehler, G | 1 |
| Gerner, HJ | 1 |
| Dörsam, J | 1 |
| Serrano Brambila, EA | 1 |
| Quiroga Avila, RG | 1 |
| Lorenzo Monterrubio, JL | 1 |
| Moreno Aranda, J | 1 |
| Bemelmans, BL | 1 |
| Kiemeney, LA | 1 |
| Debruyne, FM | 1 |
| Jones, SE | 1 |
| Shuba, LM | 1 |
| Zhabyeyev, P | 1 |
| McCullough, JR | 1 |
| McDonald, TF | 1 |
| Arikian, SR | 1 |
| Casciano, J | 1 |
| Doyle, JJ | 1 |
| Tarride, JE | 1 |
| Casciano, RN | 1 |
| Roth, DL | 2 |
| Nørgaard, JP | 1 |
| Harvey, MA | 1 |
| Baker, K | 1 |
| Wells, GA | 1 |
| Hartnett, NM | 1 |
| Saver, BG | 1 |
| Wein, AJ | 2 |
| Hall, JA | 1 |
| Nelson, MA | 1 |
| Meyer, JW | 1 |
| Williamson, T | 2 |
| Wagner, S | 1 |
| Weiss, BD | 1 |
| Oka, T | 1 |
| Nakano, K | 1 |
| Kirimoto, T | 1 |
| Matsuura, N | 1 |
| Rackley, R | 1 |
| Wein, A | 1 |
| Nelson, D | 1 |
| Crandall, C | 1 |
| O'Brien, BJ | 1 |
| Goeree, R | 1 |
| Bernard, L | 1 |
| Rosner, A | 1 |
| Slagle, M | 1 |
| Youdim, K | 1 |
| Kogan, BA | 1 |
| Kell, S | 1 |
| Wilcox, DT | 1 |
| Starr, CH | 1 |
| Newton, M | 1 |
| Kosier, JH | 1 |
| Smith, D | 1 |
| Lehtoranta, K | 1 |
| Tainio, H | 1 |
| Lukkari-Lax, E | 1 |
| Tammela, TL | 1 |
| Umlauf, MG | 1 |
| Lloyd, LK | 1 |
| Hong, JY | 1 |
| Choo, MS | 1 |
| Kwon, HY | 1 |
| Chung, DY | 1 |
| Lee, KS | 1 |
| Lee, JY | 1 |
| Lee, T | 1 |
| Garely, AD | 1 |
| Burrows, LJ | 1 |
| Paulson, DF | 1 |
| Belloli, G | 1 |
| Campobasso, P | 1 |
| Mercurella, A | 1 |
| Lubel, D | 1 |
| Hjälmås, K | 1 |
| Passerini-Glazel, G | 1 |
| Chiozza, ML | 1 |
| Uchibayashi, T | 1 |
| Nakajima, K | 1 |
| Nihino, A | 1 |
| Hisazumi, H | 1 |
| Greenfield, SP | 1 |
| Fera, M | 1 |
| Carter, JP | 1 |
| Noronha-Blob, L | 1 |
| Audia, VH | 1 |
| Dupont, AC | 1 |
| McPherson, DW | 1 |
| Natalie, KJ | 1 |
| Rzeszotarski, WJ | 1 |
| Spagnuolo, CJ | 1 |
| Waid, PP | 1 |
| Kaiser, C | 1 |
| Starer, P | 1 |
| Libow, LS | 1 |
| Yamauchi, K | 1 |
| Ohashi, K | 1 |
| Inagaki, N | 1 |
| Yamaguchi, S | 1 |
| Hashimoto, H | 1 |
| Moore, KH | 1 |
| Goldstein, M | 1 |
| Hay, D | 1 |
| Tapp, AJ | 1 |
| Cardozo, LD | 1 |
| Cooper, D | 1 |
| Pummer, K | 1 |
| Yokoyama, E | 1 |
| Fujino, A | 1 |
| Kubo, S | 1 |
| Mashimo, S | 1 |
| Koshiba, K | 1 |
| Castleden, CM | 1 |
| Battcock, TM | 1 |
| Duffin, HM | 1 |
| van Waalwijk van Doorn, ES | 1 |
| Zwiers, W | 1 |
| Jakobsen, H | 1 |
| Steven, K | 1 |
| Zorzitto, ML | 1 |
| Holliday, PJ | 1 |
| Jewett, MA | 1 |
| Herschorn, S | 1 |
| Fernie, GR | 1 |
| Brendler, CB | 1 |
| Radebaugh, LC | 1 |
| Mohler, JL | 1 |
| Karram, MM | 1 |
| Bhatia, NN | 1 |
| Blaustein, J | 2 |
| Connor, A | 2 |
| Pitt, A | 1 |
| Orzeck, S | 1 |
| Yong, CL | 1 |
| Fanciullacci, F | 1 |
| Zanollo, A | 1 |
| Sandri, S | 1 |
| Catanzaro, F | 1 |
| Aubert, D | 1 |
| Hehir, M | 1 |
| Fitzpatrick, JM | 1 |
| Rosenbaum, JF | 1 |
| Pollack, MH | 1 |
| De Angelis, M | 1 |
| Martina, G | 1 |
| Caverni, L | 1 |
| Coglitore, A | 1 |
| Libanori, GP | 1 |
| Giannotti, P | 1 |
| Snustad, DG | 1 |
| Rosenthal, JT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury[NCT00224029] | Phase 4 | 24 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides[NCT02524769] | 27 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use[NCT02522936] | Phase 4 | 0 participants (Actual) | Interventional | 2018-08-01 | Withdrawn (stopped due to Due to lack of funding and necessary personnel we determined that the study could not be done.) | ||
| Investigation of the Effect of the Female Urinary Microbiome on Incontinence[NCT02835846] | Phase 4 | 35 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Vaginal Estradiol vs Oral Beta-3 Agonist for Treatment of Overactive Bladder Syndrome: A Single-Therapy, Double-Blind, Randomized Controlled Trial[NCT05221021] | Phase 4 | 152 participants (Anticipated) | Interventional | 2022-10-01 | Recruiting | ||
| To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker[NCT04693897] | 400 participants (Anticipated) | Observational [Patient Registry] | 2021-03-01 | Not yet recruiting | |||
| Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks - a Single-center Study[NCT05557279] | Phase 4 | 40 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| The Effectiveness of Parassacral Transcutaneous Stimulation Compared to Tibial Transcutaneous Stimulation, Home Protocol and Behavioral Therapy in the Treatment of Female Hyperative Bladder: Randomized Clinical Trial[NCT04909047] | 120 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| Comparison of the Efficacy and Tolerability of DITROPAN XL and DETROL LA in the Treatment of Overactive Bladder[NCT00293839] | Phase 3 | 790 participants (Actual) | Interventional | Completed | |||
| Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients - Clinical Effects and Investigating Mechanism of Action[NCT01682603] | Phase 2 | 34 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population[NCT02385500] | Phase 4 | 5 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to Insufficient or untimely patient recruitment) | ||
| Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Orthopedic Surgical Operations[NCT03232021] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2017-08-16 | Withdrawn (stopped due to All patients during the study period were subjected to peripheral blocks or were excluded from the study due to exclusion criteria) | ||
| Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Urological Surgical Operations[NCT03229668] | Phase 2/Phase 3 | 78 participants (Actual) | Interventional | 2017-07-28 | Completed | ||
| Comparison of the Efficacy of Transcutaneous Tibial Nerve Stimulation in Antimuscarinic Naive and Refractory Women With Idiopathic Overactive Bladder[NCT05668715] | 40 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | |||
| Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)[NCT00224146] | Phase 4 | 2,878 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Further Enhancing Non-pharmacologic Therapy for Incontinence[NCT00177541] | 123 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| Comparison of Virtual Pelvic Floor Physical Therapy With a Pelvic Floor Trainer in the Treatment of Stress Urinary Incontinence.[NCT06097234] | 45 participants (Anticipated) | Interventional | 2023-10-23 | Not yet recruiting | |||
| Efficacy of a Non-invasive Pelvic Floor Muscle Trainer for Treatment of Stress Urinary Incontinence[NCT05624645] | 5 participants (Actual) | Interventional | 2021-02-25 | Completed | |||
| Motor Cortical Neuromodulation With Repetitive Transcranial Magnetic Stimulation in Women With Overactive Bladder and Urgency Urinary Incontinence[NCT05099419] | Early Phase 1 | 10 participants (Anticipated) | Interventional | 2021-10-28 | Recruiting | ||
| Protocol for Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence An RCT: Hypnotherapy Or Pharmacotherapy[NCT01829425] | 165 participants (Actual) | Interventional | 2013-04-22 | Completed | |||
| Comparative Study of Safety and Efficacy Between 100 U Suburothelial Injection and 50 U Suburothelial Plus 50 U Urethral Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility[NCT02135341] | Phase 2 | 60 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome - A Prospective Randomized Controlled Comparative Study With Mono-antimuscarinic Therapy[NCT01824420] | Phase 4 | 129 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Comparative Bioavailability of Darifenacin Extended Release Oral Formulation [Darisec(R)7.5 mg vs. Enablex(R)7.5 mg]: Single-dose, Postprandial State, Randomized, Two-sequence, Two-period, Crossover Study in Healthy Volunteers.[NCT01229280] | Phase 1 | 24 participants (Anticipated) | Interventional | 2010-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline in number of daily catheterizations without leaking per day as recorded in a 3-day urinary diary. (NCT00224029)
Timeframe: 8 weeks
| Intervention | Number of Dry Catheterizations per Day (Mean) | |
|---|---|---|
| Baseline at Week 0 | Change from baseline at Week 8 | |
| Oxybutynin Transdermal System | 2.4 | 1.5 |
OAB symptoms are measured using the Overactive Bladder Questionnaire (OAB-q). The OAB-q symptom score ranges from 0-100 with higher scores indicating greater symptom severity. A change score is calculated as the post-treatment score minus the pre-treatment score. (NCT02524769)
Timeframe: 0, 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Estrogen Arm | -23 |
The investigators will determine whether any change in OAB symptoms using the OAB-q before and after treatment is associated with the change in participants' AMP levels before and after treatment. AMP activity level is measured as bacterial growth inhibition in square millimeters normalized to the total peptide bond concentration. The OAB-q symptom score ranges from 0-100 with higher scores indicating greater symptom severity. (NCT02524769)
Timeframe: 0, 12 weeks
| Intervention | Spearman's rho (Number) |
|---|---|
| Estrogen Arm | 0.60 |
The relative abundance of Lactobacillus to total microbes per sample was measured before and after treatment. The within-participant change in relative abundance of Lactobacillus was calculated subtracting pre-treatment from post-treatment. (NCT02524769)
Timeframe: 0, 12 weeks
| Intervention | proportion of total microbes (Mean) |
|---|---|
| Estrogen Arm | 0.143 |
The investigators will compare participants' AMP levels before and after treatment. AMP activity level is measured as bacterial growth inhibition in square millimeters normalized to the total peptide bond concentration. Change is calculated as the post-treatment AMP level minus the pre-treatment AMP level. (NCT02524769)
Timeframe: 0, 12 weeks
| Intervention | square millimeters per unit (Median) |
|---|---|
| Estrogen Arm | -0.11 |
The investigators will determine whether change in OAB symptoms using the OAB-q before and after treatment is associated with the change in participants' relative abundance of Lactobacillus before and after treatment. The OAB-q symptom score ranges from 0-100 with higher scores indicating greater symptom severity. (NCT02524769)
Timeframe: 0, 12 weeks
| Intervention | Spearman's rho (Number) |
|---|---|
| Estrogen Arm | -0.59 |
OAB symptoms are measured using the Overactive Bladder Questionnaire (OAB-q). The OAB-q symptom score ranges from 0-100 with higher scores indicating greater symptom severity. A change score is calculated as the post-treatment score minus the pre-treatment score. (NCT02835846)
Timeframe: 0, 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Estrogen Arm | -21 |
The investigators will determine whether any change in OAB symptoms using the OAB-q before and after treatment is associated with the change in participants' AMP levels before and after treatment. (NCT02835846)
Timeframe: 0, 12 weeks
| Intervention | Spearman's rho (Number) |
|---|---|
| Estrogen Arm | -1 |
The relative abundance of Lactobacillus to total microbes per sample was measured before and after treatment. The within-participant change in relative abundance of Lactobacillus was calculated subtracting pre-treatment from post-treatment. (NCT02835846)
Timeframe: 0, 12 weeks
| Intervention | proportion of total microbes (Mean) |
|---|---|
| Estrogen Arm | 0.275 |
The investigators will compare participants' AMP activity levels before and after treatment. AMP activity level is measured as the diffusion of AMPs in bacterial agar from the center of the well to which the patient's purified biological sample is applied. The diffusion of AMPs in the agar results in the killing of bacteria and a clearing around the well. This clearing of bacterial growth is measured in square millimeters and then normalized to the total peptide concentration. Change is calculated as the post-treatment AMP activity level minus the pre-treatment AMP activity level. (NCT02835846)
Timeframe: 0, 12 weeks
| Intervention | normalized bacterial growth inhibition (Median) |
|---|---|
| Estrogen Arm | 0.14 |
The investigators will determine whether change in OAB symptoms using the OAB-q before and after treatment is associated with the change in participants' relative abundance of Lactobacillus before and after treatment. The OAB-q symptom score ranges from 0-100 with higher scores indicating greater symptom severity. (NCT02835846)
Timeframe: 0, 12 weeks
| Intervention | Spearman's rho (Number) |
|---|---|
| Estrogen Arm | -0.32 |
(NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | participants (Number) | |
|---|---|---|
| Post-Autonomic dysreflexia | Post-Non Autonomic dysreflexia | |
| Pre-Autonomic Dysreflexia | 5 | 6 |
| Pre-Non Autonomic Dysreflexia | 1 | 22 |
"Bladder compliance is the result of a mathematical calculation of the volume required for a unit rise of pressure measured during a cystometric filling.~Bladder compliance is calculated by dividing the volume change by the change in bladder pressure (mL/cmH2O).~Efficacy:~Net change of the bladder compliance from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL/cmH2O (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 30.6 | 29.0 |
"Efficacy:~Net change of the cystometric bladder capacity (CBC) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 305.9 | 437.6 |
"Efficacy:~Net change of the detrusor pressure (Pdet) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | cmH2O (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 36.1 | 12.9 |
"Efficacy:~Net change of the Incontinence Impact Questionnaire (IIQ-7) from baseline and 12 months.~The IIQ-7 is a 7-item short forms on a 4-point scale ranging from 0 Not at all to 3 Greatly.~Total IIQ-7 score ranges = 0 to 21 The total IIQ-7 score can therefore range from 0 to 21 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 11.9 | 5.57 |
"Efficacy:~Net change of the maximum flow rate (Qmax) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL/s (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 4.56 | 3.54 |
"Efficacy:~Net change of the postvoid residual volume (PVR) from baseline and 12 months~Results:~Botulinum toxin A injection have increased postvoid residual urine volume in patients treated for bladder dysfunction.~Treat only patients who are willing and able to initiate catheterization post-treatment, if required, for urinary retention.~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 226.3 | 378.5 |
"Efficacy:~Net change of the quality of life index (QoL-I) from baseline and 12 months. The QoL-I on a 7-point scale ranging from 0 Delighted to 6 Terrible. The QoL-I ranges 0 to 6~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 4.00 | 2.21 |
"Efficacy:~Net change of the UrinaryDdistress Inventory (UDI-6) from baseline and 12 months.~The UDI-6 is a 6-item short forms on a 4-point scale ranging from 0 Not at all to 3 Greatly.~The total UDI-6 score can therefore range from 0 to 18 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 10.4 | 7.43 |
"Efficacy:~Net change of the void volume from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 79.6 | 59.2 |
Overactive Bladder questionnaire Short Form Quality of Life. Higher scores are better (better quality of life) and lower scores are worse (poorer quality of life). sub-scale score range 0-100. (NCT01829425)
Timeframe: 6 months
| Intervention | sub-scale scores (Least Squares Mean) |
|---|---|
| Hypnotherapy | 75.85 |
| Anticholinergic Medications | 80.19 |
Overactive Bladder questionnaire-Short Form Quality of Life. Higher scores are better (better quality of life) and lower scores are worse (poorer quality of life). sub-score range 0-100. (NCT01829425)
Timeframe: 2 months
| Intervention | sub-scale scores (Least Squares Mean) |
|---|---|
| Hypnotherapy | 73.96 |
| Anticholinergic Medications | 74.86 |
Overactive Bladder questionnaire-Short Form Quality of Life. Higher scores are better (higher quality of life) and lower scores are worse (poorer quality of life). score range 0-100. (NCT01829425)
Timeframe: 12 months
| Intervention | sub-scale scores (Least Squares Mean) |
|---|---|
| Hypnotherapy | 75.71 |
| Anticholinergic Medications | 81.57 |
Overactive Bladder Questionnaire Short Form symptom bother Scale. Sub-Scale range 0-100. Higher numbers are worse (more bother) and lower numbers are better (less bother) (NCT01829425)
Timeframe: 2 months
| Intervention | scores on a sub-scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | 38.17 |
| Anticholinergic Medications | 35.33 |
Overactive Bladder Questionnaire Short Form symptom bother. Sub-scale range 0-100. Higher numbers are worse (more bother) and lower numbers are better (less bother) (NCT01829425)
Timeframe: 12 months
| Intervention | sub-scale scores (Least Squares Mean) |
|---|---|
| Hypnotherapy | 32.27 |
| Anticholinergic Medications | 30.74 |
Overactive Bladder Questionnaire Short Form symptom bother. Sub-scale range 0-100. Higher numbers are worse (more bother) and lower numbers are better (less bother) (NCT01829425)
Timeframe: 6 months
| Intervention | sub-scale scores (Least Squares Mean) |
|---|---|
| Hypnotherapy | 34.61 |
| Anticholinergic Medications | 27.93 |
Differences comparing hypnotherapy to pharmacotherapy percent change in median UUI episodes (NCT01829425)
Timeframe: 6 months
| Intervention | percentage change in median UUI episodes (Median) |
|---|---|
| Hypnotherapy | 85.7 |
| Anticholinergic Medications | 83.3 |
Percent change in median UUI episodes from baseline to 12 months with comparison made between hypnotherapy & pharmacotherapy (NCT01829425)
Timeframe: 12 months
| Intervention | percentage change in median UUI episodes (Median) |
|---|---|
| Hypnotherapy | 85.7 |
| Anticholinergic Medications | 80.0 |
Percent change in UUI episodes from baseline to 2 months with comparison made between hypnotherapy & pharmacotherapy (NCT01829425)
Timeframe: Baseline and 2 month follow-up
| Intervention | percentage change in median UUI episodes (Median) |
|---|---|
| Hypnotherapy | 73 |
| Anticholinergic Medications | 88.6 |
number of voids on 3-day bladder diary (NCT01829425)
Timeframe: 12 months
| Intervention | counts (Mean) |
|---|---|
| Hypnotherapy | 25.74 |
| Anticholinergic Medications | 25.37 |
number of voids on 3-day bladder diary (NCT01829425)
Timeframe: 6 months
| Intervention | counts (Mean) |
|---|---|
| Hypnotherapy | 25.58 |
| Anticholinergic Medications | 24.28 |
Total Number of voids on 3-day bladder diary. (NCT01829425)
Timeframe: 2 months
| Intervention | counts (Mean) |
|---|---|
| Hypnotherapy | 26.4 |
| Anticholinergic Medications | 25.35 |
45 reviews available for oxybutynin and Urinary Incontinence
| Article | Year |
|---|---|
What do cochrane systematic reviews say about interventions for enuresis in children and adolescents? An overview of systematic reviews.
Topics: Adolescent; Child; Deamino Arginine Vasopressin; Enuresis; Humans; Imipramine; Nocturnal Enuresis; S | 2022 |
Fesoterodine fumarate and the oxybutynin ring for the treatment of urinary incontinence in women.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Contraceptive Devices, Female; Drug Delivery Systems; | 2014 |
Cochrane Review Summary: Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women.
Topics: Clenbuterol; Combined Modality Therapy; Duloxetine Hydrochloride; Electric Stimulation; Exercise The | 2015 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Comparative Effectiveness Research; Cresols; Female; | 2012 |
Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Chronic Disease; Cresols; Drug Combinations; Female; | 2012 |
The newer antimuscarinic drugs: bladder control with less dry mouth.
Topics: Benzhydryl Compounds; Controlled Clinical Trials as Topic; Cresols; Delayed-Action Preparations; Dos | 2002 |
Achieving bladder control. Treatment in the primary care setting.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Estrogen Replacement Therapy; Female; Humans | 2002 |
Future studies of overactive bladder: the need for standardization.
Topics: Adult; Child; Cholinergic Antagonists; Female; Forecasting; Humans; Mandelic Acids; Muscarinic Antag | 2002 |
Transdermal oxybutynin: a new treatment for overactive bladder.
Topics: Administration, Cutaneous; Administration, Oral; Clinical Trials, Phase II as Topic; Clinical Trials | 2003 |
Urinary incontinence. Solving a secret problem.
Topics: Activities of Daily Living; Attitude to Health; Behavior Therapy; Exercise Therapy; Humans; Mandelic | 2003 |
Trospium chloride in the management of overactive bladder.
Topics: Benzhydryl Compounds; Benzilates; Biological Availability; Cresols; Female; Half-Life; Humans; Male; | 2004 |
Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.
Topics: Adult; Aged; Female; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Urinary Incontinen | 2004 |
Elevating our therapeutic expectations in overactive bladder.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Constipation; Cresols; Delayed-Action Preparations; H | 2004 |
Overactive bladder: evaluation and management in primary care.
Topics: Algorithms; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cholinergic Antagonists; Cresols | 2005 |
Trospium chloride for the treatment of overactive bladder with urge incontinence.
Topics: Aging; Area Under Curve; Benzhydryl Compounds; Benzilates; Cholinergic Antagonists; Cresols; Female; | 2005 |
Assessment and management of urinary incontinence.
Topics: Aged; Behavior Therapy; Benzhydryl Compounds; Cresols; Exercise Therapy; Female; Humans; Male; Mande | 2005 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2005 |
Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations.
Topics: Benzhydryl Compounds; Cost of Illness; Cresols; Female; Humans; Male; Mandelic Acids; Markov Chains; | 2005 |
Intravesical therapy for overactive bladder.
Topics: Administration, Intravesical; Afferent Pathways; Efferent Pathways; Humans; Mandelic Acids; Muscarin | 2005 |
Anticholinergic drugs for overactive bladder.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Delayed-Action Preparations; Humans; Mandeli | 2006 |
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Cresols; Humans; Mandelic Ac | 2006 |
The emergence of new drugs for overactive bladder.
Topics: Acetylcholine; Amines; Animals; Anticonvulsants; Benzhydryl Compounds; Cresols; Cyclohexanecarboxyli | 2006 |
The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.
Topics: Administration, Cutaneous; Administration, Intravesical; Administration, Oral; Algorithms; Animals; | 2006 |
A meta-analysis comparing trials of antimuscarinic medications funded by industry or not.
Topics: Benzhydryl Compounds; Cresols; Drug Industry; Humans; Mandelic Acids; Muscarinic Antagonists; Phenyl | 2006 |
[Intravesical treatment of overactive bladder syndrome].
Topics: Administration, Intravesical; Anesthetics, Local; Botulinum Toxins, Type A; Cholinergic Antagonists; | 2006 |
Transdermal oxybutynin: sticking to the facts.
Topics: Administration, Cutaneous; Humans; Mandelic Acids; Muscarinic Antagonists; Urinary Incontinence | 2007 |
Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Collagen; Cresols; Duloxetine Hydrochloride; Electric | 2008 |
Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.
Topics: Animals; Drug Evaluation; Female; Humans; Male; Mandelic Acids; Parasympatholytics; Urinary Bladder; | 1995 |
Tolterodine.
Topics: Animals; Benzhydryl Compounds; Cholinergic Antagonists; Controlled Clinical Trials as Topic; Cresols | 1998 |
Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Clinical Trials as Topic; Cresols; Drug Evaluation; H | 1999 |
An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
Topics: Cholinergic Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Mandelic Aci | 1999 |
Muscarinic receptor antagonists in the treatment of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Clinical Trials as Topic; Cresols; Humans; Mandelic Acids; Muscar | 2000 |
Muscarinic receptor antagonists in the treatment of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Clinical Trials as Topic; Cresols; Humans; Mandelic Acids; Muscar | 2000 |
Muscarinic receptor antagonists in the treatment of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Clinical Trials as Topic; Cresols; Humans; Mandelic Acids; Muscar | 2000 |
Muscarinic receptor antagonists in the treatment of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Clinical Trials as Topic; Cresols; Humans; Mandelic Acids; Muscar | 2000 |
Intravesical treatment of overactive bladder.
Topics: Administration, Intravesical; Anesthetics, Local; Atropine; Capsaicin; Cholinergic Antagonists; Dite | 2000 |
A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder.
Topics: Benzhydryl Compounds; Budgets; Cholinergic Antagonists; Cost of Illness; Cost-Benefit Analysis; Cres | 2000 |
Advancements in pharmacologic management of the overactive bladder.
Topics: Adrenergic alpha-Antagonists; Aged; Animals; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; | 2000 |
Overactive bladder: optimizing quality of care.
Topics: Aged; Algorithms; Behavior Therapy; Benzhydryl Compounds; Cresols; Female; Humans; Mandelic Acids; M | 2001 |
Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.
Topics: Administration, Intravesical; Child; Cholinergic Antagonists; Humans; Mandelic Acids; Spinal Cord In | 2001 |
Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Female; Humans; Mandelic Acids; Muscarinic A | 2001 |
Tolterodine: a clinical review.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Dose-Response Relationship, Drug; Humans; Ma | 2001 |
Oxybutynin chloride: alterations in drug delivery and improved therapeutic index.
Topics: Animals; Clinical Trials as Topic; Drug Delivery Systems; Humans; Mandelic Acids; Severity of Illnes | 2002 |
Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review.
Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Drug | 2002 |
Current pharmacotherapeutic strategies for overactive bladder.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Delayed-Action Preparations; Humans; Mandeli | 2002 |
Functional daytime incontinence: pharmacological treatment.
Topics: Butylamines; Calcium Channel Blockers; Child; Humans; Mandelic Acids; Parasympatholytics; Urinary In | 1992 |
Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Double-Blind Method; Evaluation Studies as Topic; | 1989 |
75 trials available for oxybutynin and Urinary Incontinence
| Article | Year |
|---|---|
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.
Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde | 2023 |
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.
Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde | 2023 |
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.
Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde | 2023 |
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.
Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde | 2023 |
Pelvic floor muscle training alone or in combination with oxybutynin in treatment of nonmonosymptomatic enuresis. A randomized controlled trial with 2-year follow up.
Topics: Brazil; Child; Child, Preschool; Combined Modality Therapy; Exercise Therapy; Female; Humans; Male; | 2019 |
Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Gels; Humans | 2015 |
Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Female; Humans; M | 2016 |
Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Topics: Adult; Chi-Square Distribution; Confidence Intervals; Czech Republic; Double-Blind Method; Female; H | 2010 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.
Topics: Administration, Cutaneous; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Femal | 2002 |
A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder.
Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Female; H | 2002 |
Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
Topics: Adolescent; Benzhydryl Compounds; Child; Child, Preschool; Cholinergic Antagonists; Cresols; Delayed | 2003 |
Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability.
Topics: Adult; Aged; Aged, 80 and over; Benzilates; Double-Blind Method; Female; Follow-Up Studies; Humans; | 2003 |
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
Topics: Administration, Oral; Aged; Benzhydryl Compounds; Constipation; Cresols; Delayed-Action Preparations | 2003 |
Transdermal oxybutynin: for overactive bladder.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Benzhydryl Compounds; Cresols; Double- | 2003 |
Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-B | 2003 |
Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence.
Topics: Aged; Delayed-Action Preparations; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Pil | 2004 |
Behavioral and drug therapy for urinary incontinence.
Topics: Aged; Aged, 80 and over; Biofeedback, Psychology; Female; Humans; Mandelic Acids; Middle Aged; Musca | 2004 |
Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience.
Topics: Administration, Intravesical; Adolescent; Aged; Cellulose; Drug Therapy, Combination; Female; Follow | 2004 |
A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence.
Topics: Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Ma | 2004 |
Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-B | 2004 |
Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder.
Topics: Cholinesterase Inhibitors; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Bli | 2004 |
Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
Topics: Adult; Benzhydryl Compounds; Cresols; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; | 2004 |
Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Cross-Over Studies; Female; Humans; M | 2004 |
Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Mandelic Acids; Middle Aged; Muscle Hypertonia; Pati | 2005 |
Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.
Topics: Accommodation, Ocular; Adult; Benzhydryl Compounds; Cresols; Eye Diseases; Humans; Intraocular Press | 2005 |
Effects of behavioral and drug therapy on nocturia in older incontinent women.
Topics: Aged; Aged, 80 and over; Behavior Therapy; Biofeedback, Psychology; Female; Humans; Mandelic Acids; | 2005 |
The effect of oxybutynin treatment on cognition in children with diurnal incontinence.
Topics: Behavior Therapy; Child; Cholinergic Antagonists; Circadian Rhythm; Cognition; Combined Modality The | 2005 |
Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Benzofurans; Cross-Over Studies; Double-Bli | 2005 |
Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzofurans; Cross-Over Studies; Double-Blind Method; Fe | 2005 |
A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation.
Topics: Administration, Oral; Adult; Aged; Combined Modality Therapy; Electric Stimulation Therapy; Female; | 2005 |
Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparatio | 2005 |
Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.
Topics: Administration, Cutaneous; Aged; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Middle Age | 2005 |
Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
Topics: Adult; Anti-Infective Agents, Urinary; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; H | 2006 |
Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
Topics: Adult; Anti-Infective Agents, Urinary; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; H | 2006 |
Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
Topics: Adult; Anti-Infective Agents, Urinary; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; H | 2006 |
Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
Topics: Adult; Anti-Infective Agents, Urinary; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; H | 2006 |
[Intravesical therapy for overactive bladder].
Topics: Administration, Intravesical; Adolescent; Adult; Capsaicin; Child; Child, Preschool; Drug Delivery S | 2006 |
A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth.
Topics: Adult; Aged; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Fem | 2006 |
Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence.
Topics: Administration, Cutaneous; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Middle Aged; M | 2006 |
Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
Topics: Benzhydryl Compounds; Child; Child, Preschool; Cresols; Female; Humans; Male; Mandelic Acids; Muscar | 2006 |
Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
Topics: Benzilates; Cross-Over Studies; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions | 2006 |
Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Electric Stimulation Therapy; Female; Humans; Mandelic A | 2006 |
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
Topics: Administration, Cutaneous; Aged; Female; Humans; Libido; Male; Mandelic Acids; Marriage; Middle Aged | 2006 |
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Mandeli | 2007 |
Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparatio | 2007 |
Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Mandelic Acids; Manometr | 1984 |
Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Therapy; Fe | 1995 |
[Topical administration of oxybutynin hydrochloride in women with urge incontinence. Results of a prospective randomized double-blind study].
Topics: Administration, Intravesical; Adult; Aged; Double-Blind Method; Female; Humans; Mandelic Acids; Midd | 1995 |
[The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
Topics: Administration, Intravesical; Adolescent; Adult; Catheterization; Child; Drug Administration Schedul | 1995 |
Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Cognition; Combined Modality Therap | 1995 |
Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Hydronephrosis; Infant; Kidney; Male; Mandelic | 1994 |
Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial.
Topics: Administration, Intravesical; Aged; Female; Humans; Mandelic Acids; Middle Aged; Parasympatholytics; | 1995 |
[Intravesical oxybutynin hydrochloride in the treatment of urge incontinence in the elderly].
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Cholinergic Antagonists; Female; Humans; Male | 1996 |
Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence.
Topics: Aged; Aged, 80 and over; Electrocardiography; Heart Rate; Humans; Mandelic Acids; Middle Aged; Paras | 1996 |
Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients.
Topics: Adult; Aged; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Doub | 1997 |
Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.
Topics: Adult; Analysis of Variance; Benzhydryl Compounds; Chi-Square Distribution; Cholinergic Antagonists; | 1997 |
Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction.
Topics: Adult; Female; Humans; Injections; Male; Mandelic Acids; Middle Aged; Parasympatholytics; Quality of | 1998 |
Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children.
Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Female; | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Biofeedback, Psychology; Female; Hu | 1998 |
Reassessing the role of urodynamics after cerebrovascular accident. Males versus females.
Topics: Administration, Oral; Aged; Cerebrovascular Disorders; Female; Humans; Male; Mandelic Acids; Middle | 1998 |
Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
Topics: Administration, Oral; Aged; Area Under Curve; Cholinergic Antagonists; Circadian Rhythm; Cross-Over | 1999 |
Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group.
Topics: Adult; Aged; Cholinergic Antagonists; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Mid | 1999 |
Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
Topics: Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Dose-Response Relationship, Drug; Double-Bl | 1999 |
Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.
Topics: Aged; Cholinergic Antagonists; Drug Administration Schedule; Female; Humans; Male; Mandelic Acids; U | 1999 |
A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence.
Topics: Benzilates; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Middle Aged; Parasympatholyti | 1999 |
Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Double-Blind | 1999 |
Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial.
Topics: Adult; Aged; Cholinergic Antagonists; Drug Combinations; Female; Humans; Mandelic Acids; Middle Aged | 2000 |
Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group.
Topics: Chemistry, Pharmaceutical; Cholinergic Antagonists; Delayed-Action Preparations; Dose-Response Relat | 2000 |
Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients.
Topics: Administration, Intravesical; Adolescent; Adult; Child; Child, Preschool; Cholinergic Antagonists; C | 2000 |
[Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women].
Topics: Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Cross-Sectional Studies; Double-Blind Metho | 2000 |
Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Female; Humans; Male; Mandelic | 2000 |
Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women.
Topics: Aged; Behavior Therapy; Biofeedback, Psychology; Double-Blind Method; Female; Humans; Mandelic Acids | 2001 |
Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Topics: Administration, Intravesical; Adolescent; Adult; Cholinergic Antagonists; Cross-Over Studies; Double | 2002 |
Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women.
Topics: Age Factors; Aged; Aged, 80 and over; Behavior Therapy; Double-Blind Method; Female; Humans; Mandeli | 2002 |
Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzhydryl Compounds; Cholinergic Antagonists; Cresols | 2002 |
[Assessment of the use of oxybutynin hydrochloride (Pollakisu tablets) in the elderly].
Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Middle Aged; Paras | 1991 |
The treatment of detrusor instability in postmenopausal women with oxybutynin chloride: a double blind placebo controlled study.
Topics: Female; Humans; Mandelic Acids; Menopause; Middle Aged; Parasympatholytics; Urinary Incontinence | 1990 |
The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Mandelic Acids; Menopause; Middle Aged | 1990 |
Lack of effect of cholinergic blocking and alpha-adrenergic stimulation on nocturnal incontinence after ileocaecal bladder replacement. A controlled randomised study.
Topics: Aged; Cecum; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Ileum; Mandelic Acids; Mid | 1989 |
Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Double-Blind Method; Evaluation Studies as Topic; | 1989 |
125 other studies available for oxybutynin and Urinary Incontinence
| Article | Year |
|---|---|
Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.
Topics: Animals; Female; Models, Molecular; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Quin | 2005 |
Severe Xerostomia Secondary to Anticholinergic Drug Therapy: Case Report.
Topics: Aged, 80 and over; Cholinergic Antagonists; Female; Humans; Mandelic Acids; Urinary Incontinence; Xe | 2017 |
Topics: Child; Humans; Mandelic Acids; Transcutaneous Electric Nerve Stimulation; Urinary Incontinence; Urin | 2018 |
Risks and benefits of bladder antimuscarinics among elderly residents of Veterans Affairs Community Living Centers.
Topics: Aged; Aged, 80 and over; Cognition; Cohort Studies; Drug Utilization; Female; Fractures, Bone; Human | 2013 |
Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Cresols; Humans; Incontinence Pads; Man | 2013 |
Upper tract changes in patients with neurogenic bladder and sustained pressures >40 cm following bladder neck surgery without augmentation.
Topics: Child; Female; Follow-Up Studies; Humans; Hydronephrosis; Male; Mandelic Acids; Muscarinic Antagonis | 2014 |
Risk of medication-associated initiation of oxybutynin in elderly men and women.
Topics: Adrenergic alpha-1 Receptor Antagonists; Age Factors; Aged; Aged, 80 and over; Dose-Response Relatio | 2014 |
New treatments for incontinence. Find out which of the latest therapies are worth trying.
Topics: Acetanilides; Botulinum Toxins, Type A; Humans; Mandelic Acids; Suburethral Slings; Thiazoles; Trans | 2014 |
Restoring continence in frail older people living in the community: what factors influence successful treatment outcomes?
Topics: Aged; Aged, 80 and over; Cognition Disorders; Comorbidity; Exercise; Female; Follow-Up Studies; Frai | 2009 |
Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Topics: Clinical Trials, Phase II as Topic; Humans; Mandelic Acids; Muscarinic Antagonists; Pyrazoles; Quali | 2010 |
Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Topics: Clinical Trials, Phase II as Topic; Humans; Mandelic Acids; Muscarinic Antagonists; Pyrazoles; Quali | 2010 |
Urinary incontinence: oxybutynin topical gel for overactive bladder.
Topics: Administration, Topical; Female; Gels; Humans; Male; Mandelic Acids; Middle Aged; Randomized Control | 2009 |
Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Topics: Administration, Cutaneous; Adult; Drug Dosage Calculations; Female; Humans; Male; Mandelic Acids; Mi | 2009 |
In women with urinary incontinence how necessary is cystometry?
Topics: Adult; Aged; Female; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Muscle Contraction | 2010 |
Detrusorectomy reduces the need for augmentation and use of antimuscarinics in children with neuropathic bladders.
Topics: Adolescent; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Muscar | 2013 |
New treatment options for overactive bladder and incontinence.
Topics: Aged; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Geriatric Assessment; Geriatric Nursin | 2002 |
Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study.
Topics: Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Delayed-Action Preparations; Female; Humans | 2002 |
Which stop test is best? Measuring detrusor contractility in older females.
Topics: Aged; Aged, 80 and over; Diagnostic Techniques, Urological; Female; Humans; Mandelic Acids; Middle A | 2003 |
The use of tolterodine in children after oxybutynin failure.
Topics: Adolescent; Benzhydryl Compounds; Child; Child, Preschool; Cholinergic Antagonists; Cresols; Cross-O | 2003 |
[Urinary incontinence--treatment].
Topics: Adrenergic Uptake Inhibitors; Behavior Therapy; Benzhydryl Compounds; Benzilates; Biofeedback, Psych | 2003 |
[Therapeutic effects of intrarectal administration of oxybutynin].
Topics: Administration, Rectal; Adult; Aged; Cholinergic Antagonists; Dose-Response Relationship, Drug; Fema | 2002 |
Effectiveness of vaginally administered oxybutynin on rabbit bladder function.
Topics: Acetylcholine; Administration, Intravaginal; Administration, Oral; Animals; Blood Pressure; Female; | 2003 |
Oxybutynin for diagnosis of infravesical obstruction in boys with urinary incontinence.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Humans; Male; Mandelic Acids; Muscarinic Antag | 2003 |
RE: Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
Topics: Benzhydryl Compounds; Child; Cholinergic Antagonists; Cresols; Delayed-Action Preparations; Dosage F | 2003 |
Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; | 2003 |
Advances in medical management of overactive bladder.
Topics: Administration, Cutaneous; Administration, Oral; Benzhydryl Compounds; Cresols; Delayed-Action Prepa | 2003 |
Transdermal oxybutynin. A viewpoint by Michael Chancellor.
Topics: Administration, Cutaneous; Delayed-Action Preparations; Erythema; Humans; Mandelic Acids; Pruritus; | 2003 |
Transdermal oxybutynin. A viewpoint by Adrian Wagg.
Topics: Administration, Cutaneous; Adult; Aged; Delayed-Action Preparations; Humans; Mandelic Acids; Skin; U | 2003 |
Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder.
Topics: Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Mult | 2004 |
Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Delayed-Action | 2004 |
Transdermal oxybutynin (oxytrol) for urinary incontinence.
Topics: Administration, Cutaneous; Cholinergic Antagonists; Drug Administration Schedule; Drug Costs; Humans | 2004 |
[Therapy of bladder weakness].
Topics: Adult; Benzhydryl Compounds; Child; Child, Preschool; Cresols; Humans; Mandelic Acids; Muscarinic An | 2005 |
Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
Topics: Adolescent; Behavior Therapy; Benzhydryl Compounds; Child; Child, Preschool; Cholinergic Antagonists | 2005 |
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
Topics: Benzhydryl Compounds; Central Nervous System; Cresols; Delayed-Action Preparations; Double-Blind Met | 2005 |
Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up.
Topics: Adult; Ankle; Electric Stimulation Therapy; Female; Follow-Up Studies; Humans; Mandelic Acids; Manom | 2006 |
Persistence with overactive bladder pharmacotherapy in a Medicaid population.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; | 2005 |
Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Cohort Studies; Cresols; Delayed-Action Preparations; | 2005 |
Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
Topics: Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Insurance Coverage | 2005 |
Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
Topics: Aged; Benzhydryl Compounds; Cohort Studies; Cresols; Delayed-Action Preparations; Health Care Costs; | 2005 |
[Transdermal system].
Topics: Administration, Cutaneous; Drug Administration Schedule; Humans; Mandelic Acids; Randomized Controll | 2005 |
Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.
Topics: Animals; Benzhydryl Compounds; Cresols; Male; Mandelic Acids; Muscarinic Antagonists; Phenylpropanol | 2005 |
Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
Topics: Administration, Cutaneous; Administration, Oral; Aged, 80 and over; Chemistry, Pharmaceutical; Const | 2005 |
Bladder-health diaries: an assessment of 3-day vs 7-day entries.
Topics: Benzhydryl Compounds; Chi-Square Distribution; Cresols; Humans; Mandelic Acids; Medical Records; Mus | 2005 |
Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.
Topics: Accommodation, Ocular; Benzhydryl Compounds; Cresols; Eye Diseases; Humans; Mandelic Acids; Muscarin | 2005 |
Contemporary treatment options for overactive bladder.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Exercise; Female; Humans; Life Style; Male; Mandelic Aci | 2005 |
Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity.
Topics: Administration, Intravesical; Analysis of Variance; Animals; Benzhydryl Compounds; Cresols; Female; | 2006 |
Intravesical oxybutynin: practicalities of clinical use.
Topics: Administration, Intravesical; Cholinergic Antagonists; Female; Humans; Mandelic Acids; Patient Satis | 2006 |
[Cutaneous administration rather than swallowing].
Topics: Administration, Cutaneous; Aged; Cholinergic Antagonists; Humans; Mandelic Acids; Muscle Hypertonia; | 2005 |
Frequency of wetting is predictive of response to anticholinergic treatment in children with overactive bladder.
Topics: Adolescent; Biofeedback, Psychology; Child; Child, Preschool; Female; Humans; Male; Mandelic Acids; | 2006 |
Omnibus permutation tests of the overall null hypothesis in datasets with many covariates.
Topics: Computer Simulation; Data Interpretation, Statistical; Gene Expression Profiling; Glucose Intoleranc | 2006 |
Prediction of Medicare drug formulary drugs for treatment of overactive bladder.
Topics: Cholinergic Antagonists; Drug Costs; Drug Industry; Formularies as Topic; Humans; Insurance, Pharmac | 2006 |
Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin.
Topics: Child; Child, Preschool; Delayed-Action Preparations; Female; Humans; Male; Mandelic Acids; Muscarin | 2006 |
Analysis of pharmacological effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects.
Topics: Animals; Benzilates; Butylamines; Guinea Pigs; Humans; Mandelic Acids; Muscarinic Antagonists; Muscl | 2007 |
Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
Topics: Adolescent; Child; Cholinergic Antagonists; Female; Follow-Up Studies; Humans; Hydronephrosis; Kidne | 2007 |
The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers.
Topics: Humans; Mandelic Acids; Muscarinic Antagonists; Receptor, Muscarinic M1; Receptor, Muscarinic M2; Re | 2007 |
Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Benzhydryl Compounds; Cholinergic Antagonists; | 2008 |
Intermittent catheterization: evaluation of complete dryness and independence in children with myelomeningocele.
Topics: Adolescent; Adult; Bacteriuria; Child; Child, Preschool; Combined Modality Therapy; Epinephrine; Eva | 1984 |
Long-term results of bladder transection for urge incontinence.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Middle Aged; Urinary Bladder; | 1983 |
Long-term changes in urodynamic studies of voiding in the elderly.
Topics: Aged; Aged, 80 and over; Female; Humans; Male; Mandelic Acids; Middle Aged; Parasympatholytics; Uret | 1994 |
Plasma levels of oxybutynine chloride in children.
Topics: Adolescent; Aging; Body Weight; Child; Child, Preschool; Female; Humans; Male; Mandelic Acids; Paras | 1994 |
Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Humans; Male; Mandelic Acids; Meningomyelocele; | 1994 |
The use of Ditropan in the elderly: nursing responsibilities.
Topics: Aged; Geriatric Nursing; Humans; Mandelic Acids; Parasympatholytics; Urinary Incontinence | 1993 |
Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients.
Topics: Administration, Intravesical; Adolescent; Adult; Child; Child, Preschool; Female; Follow-Up Studies; | 1994 |
[Anticholinergic therapy of urinary incontinence and urinary frequency associated with the elderly--with special reference to dementia].
Topics: Aged; Aged, 80 and over; Butylamines; Dementia; Drug Administration Schedule; Drug Therapy, Combinat | 1993 |
[Topical treatment with oxybutynin chloride in neurogenic incontinence].
Topics: Administration, Topical; Adolescent; Child; Child, Preschool; Female; Humans; Male; Mandelic Acids; | 1993 |
Intravesical oxybutynin chloride: experience with 42 patients.
Topics: Administration, Intravesical; Adolescent; Adult; Aged; Female; Follow-Up Studies; Humans; Male; Mand | 1993 |
Urge incontinence in elderly people: factors predicting the severity of urine loss before and after pharmacological treatment.
Topics: Aged; Aged, 80 and over; Cholinergic Antagonists; Female; Humans; Male; Mandelic Acids; Middle Aged; | 1996 |
Case 7: the addled nonagenarian.
Topics: Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Confusion; Depressive Diso | 1995 |
Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency.
Topics: Animals; Atropine; Benzilates; Calcium Channel Blockers; Denervation; Disease Models, Animal; Flavox | 1997 |
The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study.
Topics: Administration, Oral; Female; Humans; Mandelic Acids; Parasympatholytics; Patient Compliance; Pilot | 1997 |
Intravesical therapy for the treatment of neurogenic bladder in children.
Topics: Administration, Intravesical; Child; Child, Preschool; Cholinergic Antagonists; Drug Therapy, Combin | 1997 |
Mechanical misadministration of an oral hypoglycemic agent.
Topics: Administration, Oral; Aged; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Mandelic Aci | 1997 |
Oxybutynin and intranasal desmopressin for clozapine-induced urinary incontinence.
Topics: Administration, Intranasal; Adult; Ambulatory Care; Clozapine; Deamino Arginine Vasopressin; Female; | 1997 |
[Management of hyposalivation caused by oxybutynin chloride in the treatment of the unstable bladder].
Topics: Adult; Cholinergic Antagonists; Female; Humans; Male; Mandelic Acids; Urinary Incontinence; Xerostom | 1998 |
Acute-angle closure glaucoma as a side-effect of oxybutynin.
Topics: Acute Disease; Aged; Aged, 80 and over; Cholinergic Antagonists; Female; Glaucoma, Angle-Closure; Hu | 1998 |
The use of salivary stimulant pastilles to improve compliance in women taking oxybutinin hydrochloride for detrusor instability.
Topics: Anethole Trithione; Bromhexine; Female; Humans; Mandelic Acids; Parasympatholytics; Patient Complian | 1998 |
Incontinence after surgery for benign prostatic hypertrophy: the case for complex approach and treatment.
Topics: Aged; Aged, 80 and over; Follow-Up Studies; Humans; Incidence; Male; Mandelic Acids; Middle Aged; Pr | 1998 |
[Neuropsychiatric adverse effects attributed to use of oxybutynin].
Topics: Aged; Aged, 80 and over; Child; Enuresis; Female; Humans; Male; Mandelic Acids; Mental Disorders; Pa | 1998 |
Treatment of detrusor instability with oxybutynin rectal suppositories.
Topics: Administration, Rectal; Aged; Cholinergic Antagonists; Female; Follow-Up Studies; Humans; Mandelic A | 1998 |
Urodynamic variables cannot be used to classify the severity of detrusor instability.
Topics: Female; Humans; Mandelic Acids; Middle Aged; Parasympatholytics; Pressure; Prospective Studies; Trea | 1998 |
[Neuro-urological findings in Williams syndrome: report of a case].
Topics: Child; Female; Humans; Mandelic Acids; Urinary Incontinence; Williams Syndrome | 1998 |
Improving treatment of urinary incontinence.
Topics: Behavior Therapy; Biofeedback, Psychology; Humans; Mandelic Acids; Parasympatholytics; Urinary Incon | 1998 |
Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder.
Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Female; Humans; Infant; Male; Man | 1998 |
Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia.
Topics: Administration, Intravesical; Humans; Mandelic Acids; Multiple Sclerosis; Parasympatholytics; Reflex | 1993 |
Clinical efficacy of oxybutynin on sensory urgency as compared with that on motor urgency.
Topics: Aged; Cholinergic Antagonists; Humans; Mandelic Acids; Muscle Contraction; Muscle, Smooth; Severity | 1999 |
Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cohort Studies; Cresols; Drug Pres | 2000 |
[Intravesical drug therapy in women with severe urge incontinence. Clinical experiences from a department of gynecology].
Topics: Administration, Intravesical; Adult; Aged; Cholinergic Antagonists; Emepronium; Female; Humans; Mand | 1999 |
Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials.
Topics: Action Potentials; Animals; Butylamines; Dose-Response Relationship, Drug; Drug Interactions; Guinea | 2000 |
Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder?
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Delayed-Action Preparations; Double-Blind Me | 2001 |
Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin.
Topics: Aged; Behavior Therapy; Benzhydryl Compounds; Combined Modality Therapy; Cresols; Female; Humans; Ma | 2000 |
Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Comorbidity; Cost of Illness; Cresols; Female; Health | 2001 |
POEMS (patient-oriented evidence that matters) spark discussion.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Clinical Trials as Topic; Cresols; Delayed-Action Pre | 2001 |
Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats.
Topics: Administration, Oral; Animals; Basal Nucleus of Meynert; Benzilates; Cognition Disorders; Consciousn | 2001 |
Medical treatment of overactive bladder.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Cresols; Delayed-Action Preparations; Humans; Mandel | 2001 |
Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective.
Topics: Benzhydryl Compounds; Canada; Cost-Benefit Analysis; Cresols; Economics, Pharmaceutical; Humans; Man | 2001 |
Medication update.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cholinergic An | 2002 |
Preliminary study of the safety and efficacy of extended-release oxybutynin in children.
Topics: Adolescent; Child; Child, Preschool; Delayed-Action Preparations; Humans; Mandelic Acids; Retrospect | 2002 |
The management of urinary incontinence in the exstrophy complex, posterior urethral valves, and infrasphincteric ureters.
Topics: Bladder Exstrophy; Catheterization; Child; Cholinergic Antagonists; Epispadias; Female; Humans; Inte | 2002 |
Treatment can lead to a long dry spell.
Topics: Behavior Therapy; Benzhydryl Compounds; Cresols; Female; Humans; Male; Mandelic Acids; Muscarinic An | 2002 |
Treatments for overactive bladder.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Female; Humans; Male; Mandelic Acids; Phenyl | 2000 |
S-oxybutynin.
Topics: Humans; Mandelic Acids; Urinary Incontinence | 2002 |
Advances in anticholinergic therapy delivery systems.
Topics: Administration, Cutaneous; Administration, Intravesical; Administration, Oral; Administration, Recta | 2002 |
Oxybutynin chloride in the management of idiopathic detrusor instability.
Topics: Adult; Cyclohexanes; Female; Humans; Mandelic Acids; Muscle, Smooth; Parasympatholytics; Urinary Bla | 1979 |
Neuropathic urinary incontinence in pediatric patients: management with artificial sphincter.
Topics: Adolescent; Adult; Female; Humans; Male; Mandelic Acids; Meningomyelocele; Parasympatholytics; Treat | 1992 |
Low dose oxybutynin for the unstable bladder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Drug Administration Schedule; Female; Humans; Mal | 1992 |
Oxybutynin and incontinence during grand mal seizures.
Topics: Adult; Epilepsy, Tonic-Clonic; Humans; Male; Mandelic Acids; Parasympatholytics; Urinary Incontinenc | 1991 |
The use of intravesical oxybutynin chloride in children with neurogenic bladder.
Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Female; Humans; Male; Mandelic Ac | 1991 |
Analogues of oxybutynin. Synthesis and antimuscarinic and bladder activity of some substituted 7-amino-1-hydroxy-5-heptyn-2-ones and related compounds.
Topics: Alkynes; Amines; Animals; Carbachol; Cyclobutanes; Female; Guinea Pigs; Mandelic Acids; Muscarinic A | 1991 |
Persistence of detrusor hyperreflexia in a continent, institutionalized elderly patient with Parkinson's disease.
Topics: Aged; Humans; Male; Mandelic Acids; Parasympatholytics; Parkinson Disease; Reflex, Abnormal; Urinary | 1991 |
[Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence].
Topics: Administration, Oral; Drug Administration Schedule; Drug Evaluation; Humans; Mandelic Acids; Polyuri | 1990 |
Oxybutynin hydrochloride in the management of detrusor instability.
Topics: Female; Humans; Male; Mandelic Acids; Parasympatholytics; Urinary Bladder; Urinary Incontinence; Uro | 1990 |
[Clinical effect of oxybutynin hydrochloride (1 mg/tablet)].
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Female; Humans; Male; Mandelic Acids; Middle A | 1990 |
Oxybutynin and urinary incontinence.
Topics: Aged; Humans; Mandelic Acids; Urinary Incontinence | 1990 |
Ambulant monitoring to assess the efficacy of oxybutynin chloride in patients with mixed incontinence.
Topics: Adult; Female; Humans; Male; Mandelic Acids; Monitoring, Physiologic; Muscle Contraction; Parasympat | 1990 |
Topical oxybutynin chloride for relaxation of dysfunctional bladders.
Topics: Administration, Intravesical; Aged; Child; Humans; Mandelic Acids; Middle Aged; Parasympatholytics; | 1989 |
Management of coexistent stress and urge urinary incontinence.
Topics: Adult; Aged; Drug Therapy, Combination; Estrogens; Female; Humans; Imipramine; Mandelic Acids; Middl | 1989 |
Habit training and oxybutynin for incontinence in nursing home patients: a placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Bacteriuria; Drug Evaluation; Female; Humans; Male; Mandelic Acids; Nursing | 1988 |
Pharmacokinetics and clinical effects of oxybutynin in geriatric patients.
Topics: Aged; Aged, 80 and over; Blood Pressure; Female; Heart Rate; Humans; Intraocular Pressure; Male; Man | 1988 |
Terodiline and oxybutynin in detrusor instability.
Topics: Butylamines; Calcium Channel Blockers; Female; Humans; Mandelic Acids; Parasympatholytics; Urinary I | 1988 |
The neuropathic bladder in children with spinal cord injury.
Topics: Catheterization; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Kidney Diseases; Male; | 1988 |
[Oxybutynin chloride in pediatrics: extenuating circumstances].
Topics: Child; Chlorides; Humans; Mandelic Acids; Parasympatholytics; Urinary Incontinence | 1988 |
Oxybutinin and the prevention of urinary incontinence in spina bifida.
Topics: Adolescent; Adult; Child; Female; Humans; Male; Mandelic Acids; Parasympatholytics; Prospective Stud | 1985 |
Treatment-emergent incontinence with lithium.
Topics: Adult; Aged; Bipolar Disorder; Female; Humans; Imipramine; Lithium; Lithium Carbonate; Mandelic Acid | 1985 |
Tethered cord syndrome in an adult. Pharmacological treatment of the urological symptomatology by oxybutynin.
Topics: Adult; Female; Humans; Mandelic Acids; Parasympatholytics; Spinal Cord; Tomography, X-Ray Computed; | 1986 |
Urinary incontinence in the elderly.
Topics: Aged; Female; Humans; Imipramine; Mandelic Acids; Muscle, Smooth; Parasympatholytics; Propantheline; | 1985 |